Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

WIPO - WORLD PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATIONS PUBLISHED IN 2013



Publication No.: WO2013000778A1  Published: 03/Jan/2013

Title: APPLICATOR SYSTEM FOR APPLYING A VISCOUS LIQUID TO THE HUMAN SKIN

Applicant/Assignee: FERRING B.V

Application No.: WO2012EP61784 (PCT/EP2012/61784)   Filing Date: 20/Jun/2012

Abstract:

The application relates to an applicator system (1) for applying a viscous liquid, in particular a transdermal pharmaceutical formulation, to the human skin comprising a metering dispenser (2) in turn comprising a container holding the viscous liquid and a pump (5) for metering the liquid and an applicator (3) detachably connected to the dispenser (2) and comprising an application surface (6) for receiving a metered amount of the liquid from the dispenser (2). The application surface (6) is convex.

Priority: EP20110171533 Applic. Date: 2011-06-27; US201161501292P Applic. Date: 2011-06-27

Inventor: CARRARA DARIO [CH]; BURKE JOHN EDWARD [GB]; ROBINSON DAVID GEORGE [GB]; FERNALL ROBERT PETER [GB]


Publication No.: WO2013000876A1  Published: 03/Jan/2013

Title: AN AQUEOUS COMPOSITION COMPRISING A BIOLOGICAL ANTIGEN AND AN ACRYLIC ACID POLYMER

Applicant/Assignee: INTERVET INTERNATIONAL B.V

Application No.: WO2012EP62279 (PCT/EP2012/62279)   Filing Date: 26/Jun/2012

Abstract:

The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity higher than the osmolarity of a 0.9% (w/v) sodium chloride solution in water. The invention also pertains to the acrylic acid polymer for use in a one shot vaccine against porcine circo virus 2 (PCV2) and optionally Mycoplasma hyopneumoniae and in an aqueous composition for reducing fever induced by the biological antigens present in the aqueous composition when the composition is administered to a subject animal.

Priority: US201161501866P Applic. Date: 2011-06-28; EP20110171448 Applic. Date: 2011-06-27

Inventor: MOMBARG ERWIN [NL]


Publication No.: WO2013000909A1  Published: 03/Jan/2013

Title: TOPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING SORAFENIB

Applicant/Assignee: BAYER INTELLECTUAL PROPERTY GMBH

Application No.: WO2012EP62354 (PCT/EP2012/62354)   Filing Date: 26/Jun/2012

Abstract:

The present invention relates to topical ophthalmological pharmaceutical compositions containing sorafenib or a pharmaceutically acceptable salt thereof or a polymorph, hydrate or solvate thereof and its process of preparation and its use for treating ophthalmological disorders.

Priority: EP20110171715 Applic. Date: 2011-06-28; EP20120161989 Applic. Date: 2012-03-29

Inventor: BOETTGER MICHAEL [DE]; FREUNDLIEB JULIA [DE]; HIRTH-DIETRICH CLAUDIA [DE]; KLAR JUERGEN [DE]; MUENSTER UWE [DE]; OHM ANDREAS [DE]; RIEDL BERND [DE]


Publication No.: WO2013000917A1  Published: 03/Jan/2013

Title: TOPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB

Applicant/Assignee: BAYER INTELLECTUAL PROPERTY GMBH, BAYER PHARMA AKTIENGESELLSCHAFT

Application No.: WO2012EP62365 (PCT/EP2012/62365)   Filing Date: 26/Jun/2012

Abstract:

The present invention relates to topical ophthalmological pharmaceutical compositions containing regorafenib, a hydrate, solvate or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating ophthalmological disorders.

Priority: EP20110171719 Applic. Date: 2011-06-28; EP20120155281 Applic. Date: 2012-02-14

Inventor: BOETTGER MICHAEL [DE]; DEGENFELD GEORGES [DE]; FREUNDLIEB JULIA [DE]; HIRTH-DIETRICH CLAUDIA [DE]; KELDENICH JOERG [DE]; KLAR JUERGEN [DE]; MUENSTER UWE [DE]; OHM ANDREAS [DE]; RICHTER ANNETT [DE]; RIEDL BERND [DE]


Publication No.: WO2013001073A1  Published: 03/Jan/2013

Title: A NEW STABLE ANESTHETIC COMPOSITION FOR REDUCING SKIN REACTIONS

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2012EP62731 (PCT/EP2012/62731)   Filing Date: 29/Jun/2012

Abstract:

A composition with reduced degradation rate and/or improved stability of its components and decreasing of alleviating or even annihilating cutaneous reactions comprising an emulsion with an oil phase and an aqueous phase, said oil phase being a eutectic mixture of at least one anesthetic compound and at least one adrenergic receptor agonist and method use.

Priority: FR20110056041 Applic. Date: 2011-07-05; US201161502480P Applic. Date: 2011-06-29

Inventor: PORTAL THIBAUD [FR]


Publication No.: WO2013001126A1  Published: 03/Jan/2013

Title: ACYLATION METHOD FOR PRODUCING FOOD AND/OR PHARMACEUTICAL COMPOUNDS USING FUNGAL STEROL ESTERASES

Applicant/Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Application No.: WO2012ES70473 (PCT/ES2012/70473)   Filing Date: 27/Jun/2012

Abstract:

The invention relates to a method for the acylation of free phytosterols or saturated derivatives thereof with an acylation agent selected from the group consisting of a free fatty acid and a fatty acid ester, catalysed by a sterol esterase enzyme, characterised in that said method comprises an acylation reaction in the presence of a sterol esterase produced by fungi of the genus Ophiostoma, preferably of the species O. piceae. The invention also relates to esters of phytosterols or of the saturated derivatives thereof produced by the above-mentioned method. The invention further relates to a product enriched by the esters of phytosterols or of the saturated derivatives of those of the invention, selected from a food, a food preparation, a dietary supplement and a medicament, and to the use of any of these products to reduce the cholesterol levels in blood plasma.

Priority: ES20110031098 Applic. Date: 2011-06-29

Inventor: BARBA CEDILLO VICTOR [ES]; PRIETO ORZANCO ALICIA [ES]; MARTINEZ FERRER ANGEL T [ES]; MARTINEZ FERNANDEZ MARIA JESUS [ES]


Publication No.: WO2013001167A1  Published: 03/Jan/2013

Title: NON-TOXIC COMPOSITIONS FOR DECREASING THE RISK OF CANCER CAUSED BY ORAL MICROBES

Applicant/Assignee: BIOHIT OYJ

Application No.: WO2012FI50680 (PCT/FI2012/50680)   Filing Date: 28/Jun/2012

Abstract:

The present invention concerns a product in the form of a non-toxic liquid composition, such as a mouthwash, or in the form of an effervescent tablet,for decreasing the risk of cancer caused by oral microbes,which composition comprises cysteine or a derivative thereof. Alternatively, the product may be in the form of a non-toxic combination product including an effervescent tablet, a powder or granules comprising cysteine or a derivative thereof and a mouthwash, the combination product being intended for decreasing the risk of cancer caused by oral microbes. The components of the combination product may be administered either at the same time or separately.

Priority: FI20110005680 Applic. Date: 2011-06-29

Inventor: SALASPURO MIKKO [FI]; SUOVANIEMI OSMO [FI]


Publication No.: WO2013001310A1  Published: 03/Jan/2013

Title: MACROCYCLIC COMPOUNDS AND THEIR USE AS CDK8 INHIBITORS

Applicant/Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO)

Application No.: WO2012GB51526 (PCT/GB2012/51526)   Filing Date: 29/Jun/2012

Abstract:

There is provided compounds of formula I, wherein R1, R2, R3, R4, X, Y, Z and ring A have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Priority: EP20110382222 Applic. Date: 2011-06-30

Inventor: PASTOR FERNANDEZ JOAQUIN [ES]; ALVAREZ ESCOBAR ROSA MARIA [ES]; VARELA BUSTO CARMEN [ES]; GARCIA GARCIA ANA BELEN [ES]; DIMITRIEVICH ZARICH NATASHA [ES]; BLANCO APARICIO CARMEN [ES]; RODRIGUEZ LOPEZ ANA [GB]; OYARZABAL SANTAMARINA JULEN [ES]; BISCHOFF JAMES ROBERT [BE]


Publication No.: WO2013002421A1  Published: 03/Jan/2013

Title: ANTIMICROBIAL COMPOSITION

Applicant/Assignee: TAKASAGO INTERNATIONAL CORPORATION

Application No.: WO2012JP67261 (PCT/JP2012/67261)   Filing Date: 29/Jun/2012

Abstract:

The objective of the present invention is to provide an antimicrobial composition that can be safely used with a broad range of foods and beverages, cosmetics, drugs, and other similar products while showing growth inhibition activity against a wide variety of microorganisms. The present invention relates to the antimicrobial composition comprising at least one cooling agent selected from the group consisting of menthyl 3-hydroxybutanoate, 2-methyl-3-(menthoxy)propane-1,2-diol, 2-(menthoxy)ethanol, 3-menthoxypropan-1-ol, 2-(2-menthoxyethoxy)ethanol, and menthyl glyoxylate.

Priority: JP20110146348 Applic. Date: 2011-06-30

Inventor: ISHIDA KENYA [JP]; YAMAMOTO TOMOKO [JP]; SUZUKI MIHO [JP]


Publication No.: WO2013003113A1  Published: 03/Jan/2013

Title: ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS

Applicant/Assignee: JOHNSON & JOHNSON VISION CARE, INC

Application No.: WO2012US43078 (PCT/US2012/43078)   Filing Date: 19/Jun/2012

Abstract:

The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti not inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

Priority: US201161503158P Applic. Date: 2011-06-30; US201213495049 Applic. Date: 2012-06-13

Inventor: GALLOIS ANNABELLE [US]; MOLOCK FRANK F [US]; DAVIS CARRIE L [US]; LORENZ KATHY OSBORN [US]; YOUNG JAMES K [US]; CANAVAN KRISTY L [US]; LU FANG [US]


Publication No.: WO2013003114A1  Published: 03/Jan/2013

Title: ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS

Applicant/Assignee: JOHNSON & JOHNSON VISION CARE, INC

Application No.: WO2012US43079 (PCT/US2012/43079)   Filing Date: 19/Jun/2012

Abstract:

The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

Priority: US201213495052 Applic. Date: 2012-06-13; US201161503158P Applic. Date: 2011-06-30

Inventor: GALLOIS ANNABELLE [US]


Publication No.: WO2013003445A1  Published: 03/Jan/2013

Title: TETRA-PYRIDINE COMPOUNDS AND COMPOSITION FOR PROTECTING CELLS, TISSUES AND ORGANS AGAINST ISCHEMIA-REPERFUSION INJURY

Applicant/Assignee: ATHENA CARDIONET LTD, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY, LTD, GERAGHTY, ERIN

Application No.: WO2012US44376 (PCT/US2012/44376)   Filing Date: 27/Jun/2012

Abstract:

The invention provides a novel tetra-pyridine compound and a composition containing this compound for protecting and preserving cells, tissues and organs against ischemia-reperfusion injury. A method and use of the tetra-pyridine compound for preventing or treating ischemia-reperfusion injury or for protecting and preserving excorporeal tissue or organ from ischemia and oxygen radical-related damage are also provided.

Priority: US201161503151P Applic. Date: 2011-06-30

Inventor: APPELBAUM JERACHMIEL Y [IL]; TSHUVA GOLDBERG EDIT [IL]


Publication No.: WO2013003827A2  Published: 03/Jan/2013

Title: MACROGOL 15 HYDROXYSTEARATE FORMULATIONS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US45145 (PCT/US2012/45145)   Filing Date: 29/Jun/2012

Abstract:

Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder.

Priority: US201161502637P Applic. Date: 2011-06-29

Inventor: GORE ANURADHA V [US]; WARNER KEVIN S [US]; PUJARA CHETAN P [US]; GRAHAM RICHARD S [US]; PARASHAR AJAY P [US]; LEE MU-LAN [US]; JORDAN ROBERT S [US]; LIKITLERSUANG SUKHON [US]


Publication No.: WO2013004243A1  Published: 10/Jan/2013

Title: A NICOTINE-CONTAINING CHEWING GUM PIECE PACKED IN A WRAPPING OF LAMINATE

Applicant/Assignee: FERTIN PHARMA A/S

Application No.: WO2012DK50245 (PCT/DK2012/50245)   Filing Date: 03/Jul/2012

Abstract:

A nicotine-containing chewing gum piece (1) packed in a wrapping of laminate (2), where the laminate comprises at least an inner layer (3) facing the chewing gum and a nicotine degradation agent barrier layer of a metal foil (4). The nicotine-containing chewing gum piece is shaped as an elongate plate having two ends and a thickness (t) and a length (I), where the length is in the range of 5 to 20 times the thickness (5 x t ? I < 20 x t). The wrapping has two elongate edges sealed to one another in a fin area extending along the length of the chewing gum piece and two sealed end areas (8) extending beyond the ends of the chewing gum piece.

Priority: DK20110070369 Applic. Date: 2011-07-06

Inventor: NIELSEN KAJ HOVHAVE [DK]


Publication No.: WO2013004250A1  Published: 10/Jan/2013

Title: CHEWING GUM HAVING SUSTAINED RELEASE OF NICOTINE

Applicant/Assignee: FERTIN PHARMA A/S

Application No.: WO2012DK50256 (PCT/DK2012/50256)   Filing Date: 06/Jul/2012

Abstract:

The present invention relates to a chewing gum having a high Surface Area to Volume ratio (SAV ratio), wherein said chewing gum comprises a water insoluble gum base matrix, a water soluble bulk portion and nicotine, wherein the gum base matrix, nicotine and the bulk portion are mixed and extruded to form a final extruded chewing gum product having a SAV ratio above 0.7, and wherein sustained release of nicotine is facilitated by adding 0.1 -10% of C8 -C10 triglycerides by weight of the chewing gum.

Priority: DK20110000516 Applic. Date: 2011-07-06; US201213360102 Applic. Date: 2012-01-27

Inventor: NIELSEN BRUNO PROVSTGAARD [DK]; NEERGAARD JESPER [DK]


Publication No.: WO2013004658A1  Published: 10/Jan/2013

Title: FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOF.

Applicant/Assignee: TRANSGENE SA

Application No.: WO2012EP62822 (PCT/EP2012/62822)   Filing Date: 02/Jul/2012

Abstract:

The invention relates to granule formulations of 5-fluorocytosine (5-FC), and to their use for treating hyperproliferative diseases such as cancer and other disease, such as fungal diseases. The invention further relates to the manufacture of said granules.

Priority: EP20110305852 Applic. Date: 2011-07-01

Inventor: HECQ JEROME [FR]


Publication No.: WO2013004984A1  Published: 10/Jan/2013

Title: TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS

Applicant/Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO), MCNEENEY, STEPHEN, PHILLIP

Application No.: WO2011GB01031 (PCT/GB2011/01031)   Filing Date: 07/Jul/2011

Abstract:

There is provided compounds of formula (I), wherein R1, R2, X, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).

Priority: WO2011GB01031 Applic. Date: 2011-07-07

Inventor: PASTOR FERNANDEZ JOAQUIN [ES]; MARTINEZ GONZALES SONIA [ES]; MARTIN HERNANDO JOSE IGNACIO [ES]; RODRIGUEZ HERGUETA ANTONIO [ES]; RICO FERREIRA MARIA DEL ROSARIO [ES]; BLANCO APARICIO CARMEN [ES]


Publication No.: WO2013005020A1  Published: 10/Jan/2013

Title: METHOD OF PRODUCING A NEBULISER COMPOSITION

Applicant/Assignee: UNIVERSITY OF CENTRAL LANCASHIRE

Application No.: WO2012GB51543 (PCT/GB2012/51543)   Filing Date: 02/Jul/2012

Abstract:

The present invention relates to a method of producing a nebuliser composition, particularly a nebuliser composition suitable for nebulised pulmonary delivery to a patient. The method involves a) introducing a solid dosage form of the pharmaceutically active agent into a diluent

and b) dispersing and/or dissolving the pharmaceutically active agent in the diluent to form the nebuliser composition. Solid dosage forms of pharmaceutically active agents have been found to be surprisingly effective in the nebulised pulmonary delivery of the pharmaceutically active agent, especially where the solid dosage form is dispersed and/or dissolved in situ within a nebuliser and simultaneously nebulised to deliver the pharmaceutically active agent to the patient.

Priority: GB20110011250 Applic. Date: 2011-07-01

Inventor: ELHISSI ABDELBARY [GB]; JAMA FATMOHN [GB]; AHMED WAQAR [GB]; TAYLOR KEVIN [GB]


Publication No.: WO2013005226A1  Published: 10/Jan/2013

Title: A NOVEL COMBINED PHARMACEUTICAL COMPOSITION CONTAINING DICLOFENAC AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: ZOTA HEALTH CARE LTD

Application No.: WO2011IN00868 (PCT/IN2011/00868)   Filing Date: 19/Dec/2011

Abstract:

The present invention related to a synergistic pharmaceutical composition which contains more than one active ingredients which are diclofenac, glycofurol and Drotaverine with pharmaceutically accepted excipients. The present stable and effective combined composition shows enhanced efficacy and synergistic effect to provide protection from Dysmenorrhea, Gastrointestinal colic, Biliary colic, Renal colic, Dysmenorrheal and Abdominal pain associated with irritable bowel syndrome, Pre and Post lithotripsy, Post surgical smooth muscle spasm, Post-MTP (Medical termination of pregnancy) and D&C Dilatation and curettage thereof.

Priority: IN2011MU01918 Applic. Date: 2011-07-04

Inventor: ZOTA KAMLESH RAJNIKANT [IN]; AGRAWAL SANJAY [IN]; ZOTA KETAN CHANDULAL [IN]; ZOTA MANUKANT CHANDULAL [IN]; ZOTA HIMANSHU MUKTILAL [IN]


Publication No.: WO2013006364A1  Published: 10/Jan/2013

Title: ESTABLISHMENT OF PATIENT - OR PERSON - SPECIFIC CARDIAC MYOCYTE CELL LINES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (IPSCS)

Applicant/Assignee: BAYLOR RESEARCH INSTITUTE

Application No.: WO2012US44582 (PCT/US2012/44582)   Filing Date: 28/Jun/2012

Abstract:

A composition and method for generating patient-or person-specific proliferative and substantially pure cardiac myocyte cell lines from pluripotent stem cells (iPSCs) is described herein. The patient-specific cardiac myocyte cell lines of the present invention find applications in research, drug screening and autologous cell-based therapy. The method of the present invention is simple and reproducible and generates cardiac myocyte cells having high purities and proliferating capacities.

Priority: US201161504637P Applic. Date: 2011-07-05; US201213535964 Applic. Date: 2012-06-28

Inventor: MENG XINGLI [US]; SCHIFFMANN RAPHAEL [US]; SHEN JINSONG [US]


Publication No.: WO2013006458A1  Published: 10/Jan/2013

Title: METHODS AND COMPOSITIONS OF REDUCING AND PREVENTING BACTERIAL GROWTH AND THE FORMATION OF BIOFILM ON A SURFACE UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS

Applicant/Assignee: SYNEDGEN, INC

Application No.: WO2012US45003 (PCT/US2012/45003)   Filing Date: 29/Jun/2012

Abstract:

A method of treating a surface, the method comprising contacting (e.g., spraying) an effective amount of a composition comprising a chitosan (e.g., soluble or derivatized chitosan) with the surface, thereby treating the surface. Non-pharmaceutical compositions (e.g., liquid or dry powder compositions) include chitosan (e.g., a soluble or derivatized chitosan). The compounds and compositions described herein are biocompatible (e.g., non-toxic) and/or biodegradable (e.g., eco-friendly). Methods using the compositions described herein include methods of treating a surface (e.g., an inert and/or non-animal surface, e.g., a synthetic or semi-synthetic surface (e.g., cellulose, ceramic, plastic, metal, glass, wood, or stone)

or a food or food product surface, the method comprising contacting (e.g., spraying) an effective amount of a composition comprising a chitosan (e.g., a soluble or derivatized chitosan described herein) with the inert and/or non-animal surface, or the food or food product surface, thereby treating the surface.

Priority: US201161503963P Applic. Date: 2011-07-01

Inventor: TOWNSEND STACY MARIE [US]; BAKER SHENDA M [US]; WIESMANN WILLIAM P [US]


Publication No.: WO2013006613A1  Published: 10/Jan/2013

Title: METHODS OF MANUFACTURING TOPICAL COMPOSITIONS AND APPARATUS FOR SAME

Applicant/Assignee: NOVAN, INC

Application No.: WO2012US45390 (PCT/US2012/45390)   Filing Date: 03/Jul/2012

Abstract:

Provided according to some embodiments of the invention are methods of manufacturing a pharmaceutical composition. In some embodiments, such methods include homogenizing at a first excipient composition that includes a viscosity agent and at least one solvent to form a first premix composition

separately homogenizing at least one active pharmaceutical ingredient (API) and a second excipient composition to form a second premix composition

and combining the first premix composition and the second premix composition to form the composition. The pre-mixing of constituents may increase the stability of the API and provide uniformity of the dispersion of the constituents throughout the final topical composition.

Priority: US201161504626P Applic. Date: 2011-07-05; US201261610179P Applic. Date: 2012-03-13

Inventor: KOUGOULOS ELEFTHERIOS [US]; STASKO NATHAN [US]


Publication No.: WO2013006706A1  Published: 10/Jan/2013

Title: P97-ANTIBODY CONJUGATES AND METHODS OF USE

Applicant/Assignee: BIOASIS TECHNOLOGIES INC

Application No.: WO2012US45568 (PCT/US2012/45568)   Filing Date: 05/Jul/2012

Abstract:

The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.

Priority: US201161504646P Applic. Date: 2011-07-05; US201261658217P Applic. Date: 2012-06-11

Inventor: HUTCHISON ROB [CA]; VITALIS TIMOTHY Z [CA]; GABATHULER REINHARD [CA]


Publication No.: WO2013006729A2  Published: 10/Jan/2013

Title: CANNABINOID RECEPTOR BINDING AGENTS, COMPOSITIONS AND METHODS

Applicant/Assignee: WET INC

Application No.: WO2012US45613 (PCT/US2012/45613)   Filing Date: 05/Jul/2012

Abstract:

A composition comprising a cannabinoid receptor binding agent attached to a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin.

Priority: US201213541400 Applic. Date: 2012-07-03; US201161504655P Applic. Date: 2011-07-05

Inventor: BEVIER JONATHAN [US]


Publication No.: WO2013006762A2  Published: 10/Jan/2013

Title: MULTIPLE-ENZYME NANOCOMPLEXES

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: WO2012US45690 (PCT/US2012/45690)   Filing Date: 06/Jul/2012

Abstract:

Provided are nanocomplexes having at least two different enzymes and a polymeric network anchored to at least one of the enzymes. In some embodiments, the activities of the enzymes catalyze a cascade reaction.

Priority: US201161504975P Applic. Date: 2011-07-06; US201161529767P Applic. Date: 2011-08-31

Inventor: LU YUNFENG [US]; YAN MING [US]; LIU YANG [US]


Publication No.: WO2013006795A2  Published: 10/Jan/2013

Title: ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE

Applicant/Assignee: HUMANITAS INTERNATIONAL FOUNDATION

Application No.: WO2012US45767 (PCT/US2012/45767)   Filing Date: 06/Jul/2012

Abstract:

Novel compositions comprising carrageenans well as methods of their use are disclosed. Certain novel compositions are useful, inter alia, in the prevention, inhibition and/or treatment of dengue fever (DF),. dengue fever shock syndrome (DSS) or dengue hemorrhagic fever (DHF). Other compositions are useful, inter alia, for treatment of viral infections.

Priority: US201113178051 Applic. Date: 2011-07-07; US201213543152 Applic. Date: 2012-07-06

Inventor: COLMAN JOHN SCHLAFER [US]; ROMERO LUIS RAMON [US]


Publication No.: WO2013006809A2  Published: 10/Jan/2013

Title: AEROSOLIZING PARTICLES

Applicant/Assignee: BREATHABLE FOODS, INC

Application No.: WO2012US45792 (PCT/US2012/45792)   Filing Date: 06/Jul/2012

Abstract:

A composition comprising: caffeine

a vitamin

and a sweetener.

Priority: US201161504967P Applic. Date: 2011-07-06

Inventor: EDWARDS DAVID A [US]; MAN JONATHAN [US]; KAMLER JONATHAN JACQUES [US]; BRETILLOT MARC [FR]


Publication No.: WO2013006841A1  Published: 10/Jan/2013

Title: STIMULATION OF ARTERIAL COLLATERAL GROWTH AND LYMPHOGENESIS

Applicant/Assignee: YALE UNIVERSITY

Application No.: WO2012US45853 (PCT/US2012/45853)   Filing Date: 06/Jul/2012

Abstract:

Compositions and method for stimulating and controlling arteriogenesis and lymphatic vasculature by preventing and/or reducing the cellular interaction between RAF1 and AKT have been developed. The compositions include molecules that increase the bioavailability of non-phosphorylated RAF1, for example, the RAF1 Ser259 to Ala259 mutant in (RAF1 S259A), and AKT1 inhibitory molecules. Defects, disorders or diseases of insufficient blood or lymphatic vasculature are treated by administering to a patient in need thereof, a pharmaceutical composition comprising a molecule specifically blocking RAF 1- AKT crosstalk in a pharmaceutically acceptable carrier or excipient in an amount effective to enhance the growth of blood or lymphatic vasculature in the patient in need thereof, for example, in patients with advanced vascular diseases such as atherosclerosis, diabetes or other conditions associated with defective arterial development or arterial insufficiency such as advanced coronary, peripheral or cerebral artery diseases and ischemic cardiomyopathy. Compositions can be administered by injection or by controlled or sustained release devices, coating on devices or implants, microparticles, bulking agents or depots, or other techniques providing controlled or sustain release over a period of time effective to induce blood or lymphatic vasculature growth as desired.

Priority: US201161504889P Applic. Date: 2011-07-06

Inventor: SIMONS MICHAEL [US]; DENG YONG [US]


Publication No.: WO2013007381A1  Published: 17/Jan/2013

Title: A NEW THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT

Applicant/Assignee: BRITANNIA PHARMACEUTICALS LTD

Application No.: WO2012EP02916 (PCT/EP2012/02916)   Filing Date: 11/Jul/2012

Abstract:

The present invention relates to a pharmaceutical composition containing apomorphine as the active pharmaceutical ingredient, co-solvent, antioxidant, water having a pH greater than 4. The pharmaceutical formulation is suitable for parenteral administration for the treatment of Parkinson's disease

Priority: EP20110290320 Applic. Date: 2011-07-11

Inventor: DEY MICHAEL [GB]; RICHARD JOEL [FR]; BARONNET MARIE-MADELEINE [FR]; MONDOLY NATHALIE [FR]; BERTOCCHI LAURENT [FR]; HARNETT JEREMIAH [FR]


Publication No.: WO2013007518A1  Published: 17/Jan/2013

Title: CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE

Applicant/Assignee: SANOFI

Application No.: WO2012EP62431 (PCT/EP2012/62431)   Filing Date: 27/Jun/2012

Abstract:

The present invention relates to crystalline solvates of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride, processes for their preparation and the use thereof.

Priority: EP20110305890 Applic. Date: 2011-07-08; EP20110306033 Applic. Date: 2011-12-29

Inventor: NAGEL NORBERT [DE]; BAUMGARTNER BRUNO [DE]; BERCHTOLD HARALD [DE]; PLETTENBURG OLIVER [DE]; KADEREIT DIETER [DE]; MOHNICKE MANDY [DE]; GESSLER SIMON [DE]; TILLNER JOACHIM [DE]


Publication No.: WO2013007519A1  Published: 17/Jan/2013

Title: POLYMORPHS OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE

Applicant/Assignee: SANOFI

Application No.: WO2012EP62444 (PCT/EP2012/62444)   Filing Date: 27/Jun/2012

Abstract:

The present invention relates to new crystalline polymorphs of 6 - (Piperidin-4 -yloxy) - 2H-isoquinolin- 1 -one hydrochloride, processes for their preparation and their use, in particular for the preparation of medicaments.

Priority: EP20110305891 Applic. Date: 2011-07-08; EP20110306034 Applic. Date: 2011-12-29

Inventor: NAGEL NORBERT [DE]; BAUMGARTNER BRUNO [DE]; BERCHTOLD HARALD [DE]; PLETTENBURG OLIVER [DE]; KADEREIT DIETER [DE]; MOHNICKE MANDY [DE]; GESSLER SIMON [DE]; TILLNER JOACHIM [DE]


Publication No.: WO2013007584A1  Published: 17/Jan/2013

Title: METHOD FOR STERILISING FUNCTIONALISED COATED SURFACES CONTAINING NUCLEOTIDES AND/OR NUCLEOTIDE DERIVATIVES

Applicant/Assignee: TECHNISCHE UNIVERSITAET DRESDEN

Application No.: WO2012EP63087 (PCT/EP2012/63087)   Filing Date: 05/Jul/2012

Abstract:

The invention relates to a method for sterilising functionalised coated surfaces containing nucleotides and/or nucleotide derivatives, according to which a) the surface is coated in a functionalising manner with nucleotides and/or nucleotide derivatives such that there is an surplus thereof, wherein the surplus nucleotides and/or nucleotide derivatives as sacrificial strands are not washed out of the coating, b) the atmosphere above the coated surface is enriched with ethanol, and c) the coated surface is irradiated with ionising radiation.

Priority: DE20111051692 Applic. Date: 2011-07-08

Inventor: BREHM CHIRURGIE MECHANIK E K PETER [DE]; MUELLER MATTHIAS [DE]; REICHERT JUDITH [DE]; FOERSTER ANNE [DE]; SCHWENZER BERND [DE]; SCHARNWEBER DIETER [DE]


Publication No.: WO2013007663A1  Published: 17/Jan/2013

Title: 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF

Applicant/Assignee: TECHNISCHE UNIVERSITAET DARMSTADT

Application No.: WO2012EP63331 (PCT/EP2012/63331)   Filing Date: 06/Jul/2012

Abstract:

The invention relates to compounds that act as selective glycogen synthase kinase 3 (GSK-3) ligands and can be used for the treatment of GSK-3-mediated diseases. The compounds of the invention act as glycogen synthase kinase 3 (GSK-3) inhibitors.

Priority: DE201110106990 Applic. Date: 2011-07-08

Inventor: SCHMIDT BORIS [DE]; LO MONTE FABIO [DE]; ELDAR-FINKELMANN HAGIT [IL]; VAN LEUVEN FRED [BE]; KRAMER THOMAS [DE]


Publication No.: WO2013007698A1  Published: 17/Jan/2013

Title: PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS

Applicant/Assignee: GOSFORTH CENTRE (HOLDINGS) PTY LTD

Application No.: WO2012EP63419 (PCT/EP2012/63419)   Filing Date: 09/Jul/2012

Abstract:

An anti-epileptic agent for use in the treatment of a neurological disorder other than epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.

Priority: GB20110011712 Applic. Date: 2011-07-08

Inventor: BIRD PHILIP [AU]


Publication No.: WO2013007792A1  Published: 17/Jan/2013

Title: NOVEL TH2 POLARIZING COMPOUNDS

Applicant/Assignee: THURGAUISCHE STIFTUNG FUER WISSENSCHAFT UND FORSCHUNG

Application No.: WO2012EP63717 (PCT/EP2012/63717)   Filing Date: 12/Jul/2012

Abstract:

The present invention relates to a pharmaceutical composition, particularly to a pharmaceutical composition for use in the treatment and/or prevention of immune-mediated diseases which are characterized by a Th1 environment such as autoimmune diseases, wherein said pharmaceutical composition comprises a compound of formula (I) as defined herein. The present invention also relates to the use of a compound according to formula (I) as defined herein for activating the production of at least one Th2 polarizing cytokine in NKT cells.

Priority: EP20110174047 Applic. Date: 2011-07-14; US201161507936P Applic. Date: 2011-07-14

Inventor: GROETTRUP MARCUS [DE]; WIPF PETER [US]; MUELLER MARC [DE]; PIERCE JOSHUA [US]


Publication No.: WO2013008175A1  Published: 17/Jan/2013

Title: METHOD FOR PRODUCING TRANS-RESVERATROL AND THE ANALOGS THEREOF

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BOURGOGNE

Application No.: WO2012IB53515 (PCT/IB2012/53515)   Filing Date: 10/Jul/2012

Abstract:

The invention relates to a method for producing trans-resveratrol and the analogs thereof by means of a Wittig reaction, and to the useful synthesis intermediates according to said method. The invention also relates to novel trans-resveratrol analogs, to the pharmaceutical and cosmetic compositions comprising same, and to the uses thereof in the treatment and/or prevention of cancer, cardiovascular diseases or neurodegenerative diseases.

Priority: FR20110056293 Applic. Date: 2011-07-11

Inventor: VERVANDIER-FASSEUR DOMINIQUE [FR]; CHALAL MALIK [FR]; MEUNIER PHILIPPE [FR]


Publication No.: WO2013008253A2  Published: 17/Jan/2013

Title: IMATINIB FORMULATIONS

Applicant/Assignee: DR. REDDYS LABORATORIES LIMITED

Application No.: WO2012IN00488 (PCT/IN2012/00488)   Filing Date: 11/Jul/2012

Abstract:

Aspects of the present application relate to pharmaceutical formulations comprising imatinib or its salts, isomers, racemates, enantiomers, hydrates, solvates, metabolites, and polymorphs, and mixtures thereof. Further aspects relate to processes for preparing pharmaceutical formulations comprising imatinib or its salts, together with at least one pharmaceutically acceptable excipient.

Priority: US201161506191P Applic. Date: 2011-07-11

Inventor: KONATHAM SURESH [IN]; MALLADI MADHUSUDAN [IN]; VURE PRASAD [IN]; BISWAS MOUMITA [IN]; BHISE RAHUL [IN]; KOTA RAMESH [IN]


Publication No.: WO2013008928A1  Published: 17/Jan/2013

Title: MACROLIDE DERIVATIVE

Applicant/Assignee: TAISHO PHARMACEUTICAL CO., LTD

Application No.: WO2012JP67987 (PCT/JP2012/67987)   Filing Date: 13/Jul/2012

Abstract:

The purpose of the present invention is to provide a novel compound useful for the prevention or treatment of diseases such as cancerous angiogenesis, chronic rheumatoid arthritis, intimal hyperplasia, vascular atherosclerosis, hemorrhagic stroke, acute myocardial infarction, chronic heart failure, aneurysm, cancer metastasis, adult respiratory distress syndrome, asthma, idiopathic pulmonary fibrosis, chronic sinusitis, bronchitis or chronic obstructive pulmonary disease, or a pharmaceutically acceptable salt thereof. The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Priority: JP20110155725 Applic. Date: 2011-07-14

Inventor: KASHIMURA MASATO [JP]; OGITA HARUHISA [JP]; KAWAMURA MADOKA [JP]; TANIKAWA TETSUYA [JP]; KUBO TAKEKAZU [JP]; ASANO YASUO [JP]


Publication No.: WO2013009186A1  Published: 17/Jan/2013

Title: NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF

Applicant/Assignee: APET HOLDING B.V, RIJKSUNIVERSITEIT GRONINGEN

Application No.: WO2012NL50511 (PCT/NL2012/50511)   Filing Date: 16/Jul/2012

Abstract:

The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment.

Priority: EP20110173963 Applic. Date: 2011-07-14; US201161507663P Applic. Date: 2011-07-14

Inventor: MEIJERINK HENDRIK JAN CORNELIS [BE]; CHANGOER LEKHRAM [NL]; BLOM WILLEM [NL]; VISSER MARINELLA REGINA [NL]; FRIJLINK HENDERIK WILLEM [NL]; EISSENS ANKO CORNELUS [NL]


Publication No.: WO2013009271A1  Published: 17/Jan/2013

Title: NEW IMPROVED DRY POWDER FORMULATION

Applicant/Assignee:

Application No.: WO2012TR00096 (PCT/TR2012/00096)   Filing Date: 31/May/2012

Abstract:

The present invention relates to a novel dry powder formulation developed for use in respiratory tract diseases such as asthma and COPD.

Priority: TR20110005367 Applic. Date: 2011-06-02; TR20120005852 Applic. Date: 2012-05-21

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2013009543A1  Published: 17/Jan/2013

Title: POLYCYCLIC PYRROLIDINE-2,5-DIONE DERIVATIVES AS -FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US45438 (PCT/US2012/45438)   Filing Date: 03/Jul/2012

Abstract:

The present invention relates to novel polycyclic pyrrolidine-2, 5-dione derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators the N-formyl peptide receptor like-1 (FPRL-1) receptor.

Priority: US201161506366P Applic. Date: 2011-07-11

Inventor: BEARD RICHARD L [US]; VULIGONDA VIDYASAGAR [US]; VU THONG [US]; DONELLO JOHN E [US]; VISWANATH VEENA [US]; GARST MICHAEL E [US]


Publication No.: WO2013009607A1  Published: 17/Jan/2013

Title: COMPRESSED GAS AEROSOLS WITH ENHANCED INTENSITY AND LONGEVITY OF ACTIVES

Applicant/Assignee: S. C. JOHNSON & SON, INC

Application No.: WO2012US45730 (PCT/US2012/45730)   Filing Date: 06/Jul/2012

Abstract:

Aerosol compositions propelled by compressed gas providing enhanced intensity of one or more active components (e.g., fragrance, malodor counteractant, insecticide, disinfectant, or antimicrobial) over an extended period of time in the environment of use consistently over the life of the product. This is provided by a selected combination of spray rate and average particle size of the composition. The increased intensity over time can be further enhanced by further selection of the initial and terminal pressure under which the composition is maintained, and the pressure drop ratio, with respect to the composition product and a suitable dispensing container.

Priority: US201161457925P Applic. Date: 2011-07-08

Inventor: NGUYEN PETER N [US]; SHAH BHAVESHKUMAR [US]


Publication No.: WO2013010032A1  Published: 17/Jan/2013

Title: GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US46547 (PCT/US2012/46547)   Filing Date: 12/Jul/2012

Abstract:

Embodiments relating to gels comprising imidazoline alpha agonists, such as, without limitation, oxymetazoline or a pharmaceutically acceptable salt thereof, and methods for treating diseases, such as, without limitation, rosacea, including, for example, erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, ocular rosacea or combinations thereof

and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema or redness associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith or combinations thereof using such gels are described herein.

Priority: US201161507926P Applic. Date: 2011-07-14

Inventor: SHANLER STUART D [US]; POWALA CHRISTOPHER [US]; BROWN MARC BARRY [GB]; LIM SIAN TIONG [GB]; GREENAWAY EVANS CHARLES RODNEY [GB]


Publication No.: WO2013010041A1  Published: 17/Jan/2013

Title: FORMULATIONS OF AMIKACIN AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS

Applicant/Assignee: CARDEAS PHARMA INC

Application No.: WO2012US46559 (PCT/US2012/46559)   Filing Date: 12/Jul/2012

Abstract:

The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Priority: US201161572225P Applic. Date: 2011-07-12

Inventor: MONTGOMERY ALAN BRUCE [US]


Publication No.: WO2013010257A1  Published: 24/Jan/2013

Title: MICROWAVE VACUUM-DRYING OF ORGANIC MATERIALS

Applicant/Assignee: ENWAVE CORPORATION

Application No.: WO2012CA00677 (PCT/CA2012/00677)   Filing Date: 12/Jul/2012

Abstract:

An apparatus (20) for dehydrating organic material in batches has a processing unit (22) having a microwave-vacuum chamber (34), an input module (28) and an output module (30), with a conveyor (54) for moving the material through the chamber on a microwave-transparent window. A material reservoir (68) is arranged to receive the material exiting the output module. A conveyor (78) external to the vacuum chamber conveys material that exits the reservoir to the input module. The vacuum chamber (34), reservoir (68) and external conveyor (78) are in fluid communication to operate at a common, reduced pressure. The organic material passes through the vacuum chamber multiple times to equilibrate and dry to the desired degree.

Priority: US201161509463P Applic. Date: 2011-07-19

Inventor: FU JUN [CA]; DURANCE TIMOTHY D [CA]; YAGHMAEE PARASTOO [CA]


Publication No.: WO2013010380A1  Published: 24/Jan/2013

Title: BTK INHIBITORS

Applicant/Assignee: MERCK SHARP & DOHME CORP, MSD OSS B.V

Application No.: WO2012CN00971 (PCT/CN2012/00971)   Filing Date: 19/Jul/2012

Abstract:

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Priority: US201161509446P Applic. Date: 2011-07-19; EP20110174570 Applic. Date: 2011-07-19

Inventor: DE MAN ADRIANUS P A [NL]; STERRENBURG JAN-GERARD [NL]; RAAIJMAKERS HANS C A [NL]; KAPTEIN ALLARD [NL]; OUBRIE ARTHUR [NL]; REWINKEL JOHANNES B M [NL]; JANS CHRISTIAAN G J M [NL]; WIJKMANS JACOBUS C H M [NL]; BARF TJEERD A [NL]; COOPER ALAN B [US]; KIM RONALD M [US]; BOGA SOBHANA BABU [US]; ZHU HUGH Y [US]; GAO XIAOLEI [US]; YAO XIN [US]; ANAND RAJAN [US]; WU HAO [CN]; LIU SHILAN [CN]; YANG CHUNDAO [CN]; ALHASSAN ABDUL-BASIT [US]; WANG JAMES [US]; YU YOUNONG [US]; LIU JIAN [US]; VACCARO HENRY M [US]


Publication No.: WO2013010573A1  Published: 24/Jan/2013

Title: COMPOUNDS WITH MATRIX-METALLOPROTEINASE INHIBITORY ACTIVITY

Applicant/Assignee: UNIVERSITAET MUENSTER, SIEMENS MEDICAL SOLUTIONS USA, INC

Application No.: WO2011EP62211 (PCT/EP2011/62211)   Filing Date: 18/Jul/2011

Abstract:

The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the inhibitors of matrix-metalloproteinases (MMPs) of the invention and of the diagnostic imaging agents of the invention.

Priority: WO2011EP62211 Applic. Date: 2011-07-18

Inventor: HAUFE GUENTER [DE]; KOPKA KLAUS [DE]; WAGNER STEFAN [DE]; HUGENBERG VERENA [DE]; HERMANN SVEN [DE]; SCHAEFERS MICHAEL [DE]; KOLB HARTMUTH [US]


Publication No.: WO2013010839A1  Published: 24/Jan/2013

Title: NOVEL AND SELECTIVE CCR2 ANTAGONISTS

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2012EP63362 (PCT/EP2012/63362)   Filing Date: 09/Jul/2012

Abstract:

The present invention relates to novel and selective antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD as well as pain. Claimed are compounds of formula (I), wherein G and E are independently selected from among C-H or N

wherein A is a group selected from among wherein R6 is a group of the structure -L1-R13, wherein L1 is selected from among -NH-, and -N(C1-C4-alkyl)-, and wherein R13 is selected from among -C5-C6-heterocyclyl comprising 1 or 2 hetero atoms selected from among N, and 0, and wherein R13 is optionally substituted

The other variables are as defined in the claims

Priority: EP20110174198 Applic. Date: 2011-07-15

Inventor: EBEL HEINER [DE]; FRATTINI SARA [IT]; GIOVANNINI RICCARDO [IT]; SCHEUERER STEFAN [DE]


Publication No.: WO2013010915A1  Published: 24/Jan/2013

Title: INTRAVAGINAL DELIVERY SYSTEM

Applicant/Assignee: UNIVERSITEIT GENT

Application No.: WO2012EP63702 (PCT/EP2012/63702)   Filing Date: 12/Jul/2012

Abstract:

The present invention in general relates to an intravaginal delivery system as well as uses thereof and methods for manufacturing and use of the same. In particular the present invention relates to an intravaginal delivery system for the controlled release of one or more organic acids, such as lactic acid

said intravaginal delivery system being characterized in that it comprises a combination of ethylene vinyl acetate (EVA) copolymers and carboxylic polymers, such as for example methacrylic acid - methacrylic ester copolymers.

Priority: EP20110174103 Applic. Date: 2011-07-15

Inventor: REMON JEAN PAUL [BE]; VERVAET CHRIS [BE]; VERSTRAELEN HANS [BE]; TEMMERMAN MARLEEN [BE]


Publication No.: WO2013010942A1  Published: 24/Jan/2013

Title: COMPOSITION AND METHOD FOR TREATING HPV

Applicant/Assignee: FEMALON S.A, UNIVERSITE LIBRE DE BRUXELLES, UNIVERSITE DE LIEGE

Application No.: WO2012EP63796 (PCT/EP2012/63796)   Filing Date: 13/Jul/2012

Abstract:

The present invention relates to lyophilized compositions comprising cidofovir, hydroxypropyl methylcellulose (HPMC) or hydroxyethylcellulose (HEC) and optionally a plasticizer. In particular, the present invention relates to such compositions which form a sheet-shaped porous solid matrix. The invention also relates to methods for producing such compositions. The invention further relates to such compositions for use in treating human papillomavirus (HPV) infections and HPV-associated malignancies, in particular HPV lesions and cervical cancer.

Priority: EP20110174193 Applic. Date: 2011-07-15; US201161508473P Applic. Date: 2011-07-15

Inventor: PIETTE MARIE [BE]; EVRARD BRIGITTE [BE]; COIA ISABELLE [BE]


Publication No.: WO2013011033A1  Published: 24/Jan/2013

Title: 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF

Applicant/Assignee: BAYER INTELLECTUAL PROPERTY GMBH

Application No.: WO2012EP64021 (PCT/EP2012/64021)   Filing Date: 17/Jul/2012

Abstract:

The invention relates to novel 3-(fluorvinyl)pyrazole derivatives, to a method for producing same, to the use thereof for treating and/or preventing diseases, and to the use thereof for producing pharmaceutical products for treating and/or preventing diseases, in particular for treating and/or preventing hyperproliferative and angiogenic diseases as well as those diseases caused by a metabolic adaptation to hypoxic conditions. Such treatments can be carried out as monotherapy or also in combination with other pharmaceutical products or additional therapeutic measures.

Priority: EP20110174843 Applic. Date: 2011-07-21

Inventor: HAERTER MICHAEL [DE]; BECK HARTMUT [DE]; THIERAUCH KARL-HEINZ [DE]; ELLINGHAUS PETER [DE]; GRESCHAT SUSANNE [DE]; SCHUHMACHER JOACHIM [DE]


Publication No.: WO2013011438A1  Published: 24/Jan/2013

Title: ALGINATE TUBE DRUG DELIVERY SYSTEM AND METHOD THEREFOR

Applicant/Assignee: PIRAMAL ENTERPRISES LIMITED

Application No.: WO2012IB53599 (PCT/IB2012/53599)   Filing Date: 13/Jul/2012

Abstract:

A drug delivery system which comprises alginate tube that is prepared by coating a substrate with alginate gel. One or more therapeutic drugs may also be present in the alginate gel or in the cavity of the tube. The activity of the alginate drug delivery system is highly adjustable so that the release may be controlled as required. The rate at which the system releases the drug and the concentration of the drug released can be adjusted by varying

the number of layers of the alginate tubes, the number of open or closed ends of the tubes, or the number of tube layers containing the drug.

Priority: US201113183598 Applic. Date: 2011-07-15

Inventor: KHANDARE JAYANT J [IN]; BOLDHANE SANJAY P [IN]


Publication No.: WO2013011477A1  Published: 24/Jan/2013

Title: PHARMACEUTICAL INVENTION OF TAPENTADOL

Applicant/Assignee: TORRENT PHARMACEUTICALS LTD

Application No.: WO2012IB53683 (PCT/IB2012/53683)   Filing Date: 19/Jul/2012

Abstract:

The present invention relates to a pharmaceutical composition of tapentadol for nasal administration. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for nasal administration and its use in the treatment of pain.

Priority: IN2011MU02063 Applic. Date: 2011-07-20

Inventor: NADKARNI SUNIL SADANAND [IN]; ABRAHAM JAYA [IN]; KHATRI KAPIL [IN]; MITTAL VIPUL [IN]


Publication No.: WO2013011504A1  Published: 24/Jan/2013

Title: MATERIALS AND METHOD FOR TREATING INTERNAL BODY CAVITIES

Applicant/Assignee: THERACOAT LTD

Application No.: WO2012IL00284 (PCT/IL2012/00284)   Filing Date: 19/Jul/2012

Abstract:

The use of a thermoreversible hydrogel in a system for delivering a therapeutic agent to tissue is disclosed. The thermoreversible hydrogel is characterized by a viscosity of less than 200 Pa s over a temperature range of 4 DEG C - 12 DEG C

a viscosity of greater than 103 Pa.s at 37 DEG C

a "peel strength" adhesiveness according to ASTM standard D2256-03 of 0.5 - 5.0 N cm"2 at 37 DEG C

and flexibility sufficient such that a 3 cm2 ? 3 cm2 section of bladder tissue layered with said thermoreversible hydrogel at room temperature can be stretched to 9 cm2 x 9 cm2 without detachment of said thermoreversible hydrogel from said bladder tissue.

Priority: US201161509654P Applic. Date: 2011-07-20

Inventor: DE LA ZERDA JAIME [IL]; DOLLBERG YOSH [IL]; SHPOLANSKY URI [IL]; HAKIM GIL [IL]; KONORTY MARINA [IL]


Publication No.: WO2013012049A1  Published: 24/Jan/2013

Title: HEART FAILURE PREVENTING AGENT

Applicant/Assignee: THE UNIVERSITY OF TOKYO, THERAVALUES CORPORATION

Application No.: WO2012JP68382 (PCT/JP2012/68382)   Filing Date: 19/Jul/2012

Abstract:

Provided are a medicinal agent and a food product, both of which prevent heart diseases such as cardiomegaly and heart failure. Specifically provided is an agent for preventing a heart disease such selected from among heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.

Priority: JP20110193508 Applic. Date: 2011-09-06; JP20110158920 Applic. Date: 2011-07-20; JP20120116387 Applic. Date: 2012-05-22

Inventor: MORITA HIROYUKI [JP]; NAGAI RYOZO [JP]; NAKAYAMA ATSUKO [JP]; HASHIMOTO TADASHI [JP]


Publication No.: WO2013012692A1  Published: 24/Jan/2013

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING PLANT-BASED POLYSACCHARIDES AND USES THEREOF

Applicant/Assignee: BAUSCH & LOMB INCORPORATED

Application No.: WO2012US46573 (PCT/US2012/46573)   Filing Date: 13/Jul/2012

Abstract:

A composition for providing relief to a discomfort of an eye comprises a pharmaceutically acceptable carrier and a polysaccharide extracted from a plant source, In certain embodiments, such a polysaccharide can be extracted from mushrooms, such as from the Tremella fuciformis species. The composition is administered to an affected eye to provide such relief or discomfort.

Priority: US201161509283P Applic. Date: 2011-07-19; US201213468125 Applic. Date: 2012-05-10

Inventor: MARLOWE ZORA TERESA [US]; SARKAR PARAMITA [US]; GLASS BRIAN JOHN [US]


Publication No.: WO2013012844A1  Published: 24/Jan/2013

Title: ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2012US47024 (PCT/US2012/47024)   Filing Date: 17/Jul/2012

Abstract:

The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Priority: US201161509155P Applic. Date: 2011-07-19

Inventor: HEIM-RIETHER ALEXANDER [DE]; LIANG SHUANG [US]; PADYANA ANIL KUMAR [US]; TAYLOR STEVEN JOHN [US]; ZHANG QIANG [US]


Publication No.: WO2013012945A1  Published: 24/Jan/2013

Title: METHODS OF TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFICACY OF EXERCISE THERAPY

Applicant/Assignee: CRITICAL CARE DIAGNOSTICS, INC

Application No.: WO2012US47238 (PCT/US2012/47238)   Filing Date: 18/Jul/2012

Abstract:

Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.

Priority: US201161508923P Applic. Date: 2011-07-18; US201161509359P Applic. Date: 2011-07-19

Inventor: SNIDER JAMES V [US]; GERWIEN ROBERT W [US]


Publication No.: WO2013013172A1  Published: 24/Jan/2013

Title: INTRAVAGINAL DEVICES FOR DRUG DELIVERY

Applicant/Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION

Application No.: WO2012US47649 (PCT/US2012/47649)   Filing Date: 20/Jul/2012

Abstract:

Intravaginal drug delivery devices, including intravaginal rings, are provided herein. The devices include a reservoir of at least one vaginally administrable drug wherein the reservoir is surrounded at least in part by a hydrophilic elastomer. The devices are capable of exhibiting a substantially zero order release profile of drug over extended periods of time. Also disclosed are methods for making the devices and methods of using the devices to prevent or treat a biological condition.

Priority: US201161509694P Applic. Date: 2011-07-20; US201261655288P Applic. Date: 2012-06-04

Inventor: KISER PATRICK F [US]; JOHNSON TODD JOSEPH [US]; CLARK JUSTIN THOMAS [US]; SHELKE NAMDEV [US]; RASTOGI RACHNA [US]


Publication No.: WO2013013273A1  Published: 31/Jan/2013

Title: MODULATORS OF PROTEASE ACTIVATED RECEPTORS

Applicant/Assignee: THE UNIVERSITY OF QUEENSLAND

Application No.: WO2012AU00891 (PCT/AU2012/00891)   Filing Date: 27/Jul/2012

Abstract:

The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.

Priority: WO2011AU00959 Applic. Date: 2011-07-28; AU20110904617 Applic. Date: 2011-11-07

Inventor: FAIRLIE DAVID PAUL [AU]; LIU LIGONG [AU]; YAU MEI-KWAN [AU]; SUEN JACKY YUNG [AU]; REID ROBERT [AU]; LOHMAN RINK-JAN [AU]; IYER ABISHEK VENKATASUBRAMANIAN [AU]; LIM JUNXIAN [AU]; BROWN LINDSAY CHARLES [AU]


Publication No.: WO2013013417A1  Published: 31/Jan/2013

Title: MEDICAMENT USEFUL FOR REDUCING BLOOD SUGAR AND BODY WEIGHT HAVING THE STRUCTURE OF STILBENE COMPOUNDS

Applicant/Assignee: GUANGZHOU VELLZONE INVESTMENT DEVELOPMENT CO.LTD

Application No.: WO2011CN77765 (PCT/CN2011/77765)   Filing Date: 28/Jul/2011

Abstract:

D isclosed is medicament useful for reducing blood sugar and body weight comprising 5-O-methyl Cajanonic acid A, 5-O-methyl Cajanolactone A or Cajanolactone A and having the structure of the structure of stilbene compounds. Pharmacology experiments have proved that the abovementioned compounds can reduce the fasting blood sugar and body weight, and can be used to prepare the medicament and healthcare food for treating diabetes and adiposity, especially suitable for overweight diabetic patients.

Priority: WO2011CN77765 Applic. Date: 2011-07-28

Inventor: SHEN XIAOLING [CN]; HU YINGJIE [CN]; QIU SHENGXIANG [CN]; WANG LU [CN]; FU LINCHUN [CN]; MAI ZHAO [CN]


Publication No.: WO2013014038A1  Published: 31/Jan/2013

Title: 3-OXO-2,3-DIHYDRO-1H-INDAZOLE-4-CARBOXAMIDE DERIVATIVES AS PARP-1 INHIBITORS

Applicant/Assignee: NERVIANO MEDICAL SCIENCES S.R.L

Application No.: WO2012EP64054 (PCT/EP2012/64054)   Filing Date: 18/Jul/2012

Abstract:

There are provided 3-oxo-2,3-dihydro-lH-indazole-4-carboxamide derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Priority: EP20110175355 Applic. Date: 2011-07-26; EP20120167336 Applic. Date: 2012-05-09

Inventor: PAPEO GIANLUCA MARIANO ENRICO [IT]; BORGHI DANIELA [IT]; CARUSO MICHELE [IT]; POSTERI HELENA [IT]; KRASAVIN MIKHAIL YURIEVITCH [AU]


Publication No.: WO2013014052A1  Published: 31/Jan/2013

Title: COMPOSITION

Applicant/Assignee: GLAXOSMITHKLINE LLC

Application No.: WO2012EP64139 (PCT/EP2012/64139)   Filing Date: 19/Jul/2012

Abstract:

Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.

Priority: US201161510624P Applic. Date: 2011-07-22

Inventor: AMBERY CLAIRE LOUISE [GB]; EDWARDS CHRISTOPHER DAVID [GB]


Publication No.: WO2013014098A1  Published: 31/Jan/2013

Title: TAMPON HAVING A HOLLOW SPACE

Applicant/Assignee: MARLAFIN AG

Application No.: WO2012EP64332 (PCT/EP2012/64332)   Filing Date: 20/Jul/2012

Abstract:

The invention solves the problem of providing a tampon (1) having a hollow space for receiving a capsule. The capsule may e.g. contain a vibration element. The hollow space is formed by a hollow body (5) that is open on at least one side and is surrounded by the absorbent material (2), preferably wrapped with the latter, on at least part of its length.

Priority: EP20110175780 Applic. Date: 2011-07-28

Inventor: LOPEZ ODILO [CH]; HAMMEN AXEL [CH]


Publication No.: WO2013014196A1  Published: 31/Jan/2013

Title: AQUEOUS FORMULATION COMPRISING AT LEAST A NEUTRAL SALT AND A BIOPHARMACEUTICAL PROTEIN

Applicant/Assignee: SANDOZ AG

Application No.: WO2012EP64613 (PCT/EP2012/64613)   Filing Date: 25/Jul/2012

Abstract:

The present invention is related to a pharmaceutically acceptable aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein, wherein the concentration ratio between the biopharmaceutical protein and the neutral salt is in the range of = 0,7 and = 5.

Priority: US201161511168P Applic. Date: 2011-07-25

Inventor: PRAGL BERNT [AT]; FUERTINGER SABINE [AT]


Publication No.: WO2013014204A2  Published: 31/Jan/2013

Title: 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

Applicant/Assignee: SANOFI

Application No.: WO2012EP64628 (PCT/EP2012/64628)   Filing Date: 25/Jul/2012

Abstract:

The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Priority: EP20110305971 Applic. Date: 2011-07-26

Inventor: RUF SVEN [DE]; PERNERSTORFER JOSEF [DE]; SADOWSKI THORSTEN [DE]; HORSTICK GEORG [DE]; SCHREUDER HERMAN [DE]; BUNING CHRISTIAN [DE]; WIRTH KLAUS [DE]


Publication No.: WO2013014205A1  Published: 31/Jan/2013

Title: SUBSTITUTED 3 - (THIAZOLE - 4 - CARBONYL) - OR 3 - (THIAZOLE - 2 - CARBONYL) AMINOPROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

Applicant/Assignee: SANOFI

Application No.: WO2012EP64629 (PCT/EP2012/64629)   Filing Date: 25/Jul/2012

Abstract:

The present invention relates to compounds of the formulae (Ia) and (Ib), wherein G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae la and lb, their use and pharmaceutical compositions comprising them.

Priority: EP20110305972 Applic. Date: 2011-07-26

Inventor: RUF SVEN [DE]; PERNERSTORFER JOSEF [DE]; SADOWSKI THORSTEN [DE]; HORSTICK GEORG [DE]; SCHREUDER HERMAN [DE]; BUNING CHRISTIAN [DE]; WIRTH KLAUS [DE]


Publication No.: WO2013014263A1  Published: 31/Jan/2013

Title: LEVOMILNACIPRAN DRUG FOR FUNCTIONAL REHABILITATION AFTER AN ACUTE NEUROLOGICAL STROKE

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: WO2012EP64764 (PCT/EP2012/64764)   Filing Date: 27/Jul/2012

Abstract:

The present invention relates to the use of levomilnacipran as a drug in functional recovery after a cerebrovascular accident or head trauma. The pharmaceutical compositions containing levomilnacipran are strictly those in which the levomilnacipran/dextromilnacipran mixture does not contain more than 5 wt % of dextromilnacipran, so as to not risk compromising functional recovery due to the alpha-blocking property of the dextromilnacipran.

Priority: FR20110056917 Applic. Date: 2011-07-28

Inventor: SOKOLOFF PIERRE [FR]


Publication No.: WO2013014454A1  Published: 31/Jan/2013

Title: NEW (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL FORMULATIONS

Applicant/Assignee: ASTRAZENECA AB, ASTRAZENECA UK LIMITED

Application No.: WO2012GB51791 (PCT/GB2012/51791)   Filing Date: 26/Jul/2012

Abstract:

There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution

and further comprising one or more pharmaceutically acceptable ingredients

and to processes for obtaining them.

Priority: US201161512621P Applic. Date: 2011-07-28

Inventor: ALHUSBAN FARHAN ABDUL KARIM [GB]; GABBOTT IAN PAUL [GB]; GURURAJAN BINDHUMADHAVAN [SE]; SIEVWRIGHT DAWN [GB]; SIMPSON DAVID BRADLEY BROOK [GB]


Publication No.: WO2013014473A1  Published: 31/Jan/2013

Title: DELIVERY OF AN ACTIVE MATERIAL

Applicant/Assignee: SISAF LIMITED

Application No.: WO2012GB51842 (PCT/GB2012/51842)   Filing Date: 27/Jul/2012

Abstract:

A composition for use as a topical delivery system for an active material is provided, the composition comprising a plurality of skin cell removal particles and a plurality of active material molecules, at least some of the skin cell removal particles each carrying at least one active material molecule, wherein carrying of an active material molecule by a skin cell removal particle maintains activity of the active material molecule. A topical delivery system for an active material, and a method of topical delivery of an active material are also provided.

Priority: GB20110012950 Applic. Date: 2011-07-27

Inventor: SAFFIE-SIEBERT ROGHIEH [GB]; TORABI-POUR NASROLLAH [GB]


Publication No.: WO2013014476A1  Published: 31/Jan/2013

Title: EAR DROP COMPOSITIONS AND PROCESS FOR PRODUCING THE EAR DROP COMPOSITIONS

Applicant/Assignee: DEBRECENI EGYETEM

Application No.: WO2012HU00053 (PCT/HU2012/00053)   Filing Date: 21/Jun/2012

Abstract:

The subject of the invention is ear drop compositions, which contain adenosine or a mixture of adenosine and lecithin - as active agent. The invention is relating to the process for producing ear drop compositions applying adenosine or a mixture of adenosine and lecithin, which are applicable for treatment of inflammation of the middle ear. ?

Priority: HU20110000394 Applic. Date: 2011-07-22

Inventor: SIPKA SANDOR [HU]; KERESZTES TAMAS [HU]; SZIKLAI ISTVAN [HU]; REZES SZILARD [HU]; SZENTMIKLOSI JOZSEF [HU]; FEKETE ISTVANNE [HU]; VARNAI PETER [HU]


Publication No.: WO2013014629A1  Published: 31/Jan/2013

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING PYRROLE DIONES AND THEIR USE TO INHIBIT ANGIOGENESIS

Applicant/Assignee: CONGENIA SRL

Application No.: WO2012IB53801 (PCT/IB2012/53801)   Filing Date: 25/Jul/2012

Abstract:

The present invention relates to the use of compounds as angiogenesis inhibitors in the manufacture of a medicament for use in the treatment of disease states associated with angiogenesis, and anti-angiogenic pharmaceutical compositions containing them as active ingredient.

Priority: IT2011TO00667 Applic. Date: 2011-07-25

Inventor: PLYTE SIMON [GB]; FANCELLI DANIELE [IT]; VERASI MARIO [IT]; STORTO MARIANGELA [IT]; NOWAK-SLIWINSKA PATRYCJA [FR]


Publication No.: WO2013014680A1  Published: 31/Jan/2013

Title: METHOD FOR TREATMENT OF PAIN AND INFLAMMATION

Applicant/Assignee: CADILA HEALTHCARE LIMITED

Application No.: WO2012IN00016 (PCT/IN2012/00016)   Filing Date: 05/Jan/2012

Abstract:

The present invention relates to a method for the treatment of pain and inflammation. In particular, the present invention relates to a method for the treatment of musculo-skeletal and connective tissue pain/inflammations. Further, the invention relates to reducing the incidence and severity of adverse events resulting from administration of diclofenac. The method comprises administration of a novel and stable pharmaceutical composition of diclofenac or its salts.

Priority: IN2011MU02156 Applic. Date: 2011-07-28

Inventor: MITTAL RAVINDRA [IN]; ROY SUNILENDU BHUSHAN [IN]; KOTHARI JAY SHANTILAL [IN]; SHEIKH SHAFIQ [IN]


Publication No.: WO2013016006A1  Published: 31/Jan/2013

Title: FUNCTIONALIZED CALCIUM PHOSPHATE ARTIFICIAL BONE AND JOINT COMPOSITIONS AND METHODS OF USE AND MANUFACTURE

Applicant/Assignee: CABERTECH, INC, DUQUESNE UNIVERSITY OF THE HOLY SPIRIT

Application No.: WO2012US46444 (PCT/US2012/46444)   Filing Date: 12/Jul/2012

Abstract:

A functionalized composition and resulting functionalized body or prosthesis for in vitro and in vivo use comprising at least one calcium phosphate containing phase that is functionalized with a linker group comprising at least one of an organic acid molecule, a phosphonic acid, an amine, ?,?-dicyclohexylcarbodiimide, and 3-maleimidopropionic acid N-hydroxysuccinimide ester, wherein the linker group provides for a reactive location for the attachment of the chemical or biologically active moiety to the calcium phosphate containing phase. The functionalized compositions have a pliable physical property when mixed with water and adhere to natural bone and subsequently harden at ambient temperatures. Methods of manufacturing a functionalized artificial prosthesis that may be used as artificial bones, joints, in-vitro support structures, and in-vivo support structures for cells, tissues, organs, and nerve growth and regeneration are disclosed. Methods of repairing a bone, vertebrae, or tissue structures using the functionalized compositions are provided.

Priority: US201113193231 Applic. Date: 2011-07-28

Inventor: MCGOWAN KENNETH A [US]; GAWALT ELLEN S [US]; PALCHESKO RACHELLE [US]


Publication No.: WO2013016148A2  Published: 31/Jan/2013

Title: NATRIURETIC PEPTIDE COMPOSITIONS AND METHODS OF PREPARATION

Applicant/Assignee: MEDTRONIC, INC

Application No.: WO2012US47492 (PCT/US2012/47492)   Filing Date: 19/Jul/2012

Abstract:

Therapeutic compositions containing natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing natriuretic peptides are further described.

Priority: US201161512369P Applic. Date: 2011-07-27

Inventor: VAN ANTWERP WILLIAM [US]; JUDD DIANNE [US]; WALSH ANDREW [US]; LUO LIAN [US]


Publication No.: WO2013016255A1  Published: 31/Jan/2013

Title: WOUND-HEALING COMPOSITIONS AND METHOD OF USE

Applicant/Assignee: 3M INNOVATIVE PROPERTIES COMPANY

Application No.: WO2012US47786 (PCT/US2012/47786)   Filing Date: 23/Jul/2012

Abstract:

A composition and wound dressing for treating a skin wound is disclosed. The composition and dressing comprise a pharmaceutically acceptable carrier

an effective amount of an active ingredient of inorganic solids comprising a potassium salt, a zinc salt, a calcium salt, and a rubidium salt

and an antimicrobial biguanide compound comprising an amount effective to reduce the number of viable microorganisms at a wound site. Methods of use include contacting a wound site with the composition and/or dressing.

Priority: US201161512655P Applic. Date: 2011-07-28

Inventor: PARKS PATRICK J [US]


Publication No.: WO2013016427A1  Published: 31/Jan/2013

Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CELIAC DISEASE AND GLUTEN INTOLERANCE

Applicant/Assignee: ALVINE PHARMACEUTICALS, INC

Application No.: WO2012US48149 (PCT/US2012/48149)   Filing Date: 25/Jul/2012

Abstract:

The invention concerns methods for protecting a subject in need from a deleterious effect of gluten ingestion. The invention specifically concerns the treatment of celiac disease and gluten intolerance. The invention further provides pharmaceutical compositions for protecting a subject in need from a deleterious effect of gluten ingestion, and, in particular, for treating celiac disease and gluten intolerance. Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten- intolerance from the harmful effects of ingesting food containing gluten.

Priority: US201161511401P Applic. Date: 2011-07-25; US201161550729P Applic. Date: 2011-10-24

Inventor: ADELMAN DANIEL C DR [US]


Publication No.: WO2013016494A1  Published: 31/Jan/2013

Title: TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US48263 (PCT/US2012/48263)   Filing Date: 26/Jul/2012

Abstract:

Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.

Priority: US201161511753P Applic. Date: 2011-07-26

Inventor: GORE ANURADHA V [US]; SHANKAR SAI [US]; LIKITLERSUANG SUKHON [US]; PUJARA CHETAN P [US]; NEERVANNAN SESHA [US]


Publication No.: WO2013016501A1  Published: 31/Jan/2013

Title: FORMULATIONS OF THIOPHENE COMPOUNDS

Applicant/Assignee: VERTEX PHARMACEUTICALS INCORPORATED

Application No.: WO2012US48272 (PCT/US2012/48272)   Filing Date: 26/Jul/2012

Abstract:

A pharmaceutical composition comprises: a) polymorphic form M or tromethamine salt of Compound (1) represented by formula (I)

and b) a filler. A method of preparing a pharmaceutical composition comprises: providing a mixture of Compound (1) and a filler to form the composition of Compound (1). A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition.

Priority: US201161511648P Applic. Date: 2011-07-26; US201161511643P Applic. Date: 2011-07-26; US201161511647P Applic. Date: 2011-07-26; US201161512079P Applic. Date: 2011-07-27; US201161511644P Applic. Date: 2011-07-26; US201161545751P Applic. Date: 2011-10-11; US201261623144P Applic. Date: 2012-04-12

Inventor: CARDOSO NICHOLAS [US]; GU CHONG-HUI [US]; OJAKOVO PETER A [US]; SANGHVI TAPAN [US]; SIMONE ERIC A [US]; VERWIJS MARINUS J [US]


Publication No.: WO2013016544A2  Published: 31/Jan/2013

Title: TEMPLATED ISLET CELLS AND SMALL ISLET CELL CLUSTERS FOR DIABETES TREATMENT

Applicant/Assignee: UNIVERSITY OF KANSAS

Application No.: WO2012US48352 (PCT/US2012/48352)   Filing Date: 26/Jul/2012

Abstract:

Substrates and devices for culturing cells are disclosed, along with methods of using the same. The substrates and devices include top surfaces with one or more divots disposed therein. Each divot is defined by an opening in the top surface, a rounded bottom surface spaced from the opening, and an interior side-wall surface extending between the rounded bottom surface and the opening. The top surface of the substrates and devices are optionally walled to form wells containing one or more divots. The substrates and devices may be used for reaggregating cells, for example, to form small islet cell clusters and for high throughput testing methodologies.

Priority: US201213482671 Applic. Date: 2012-05-29; US201161512303P Applic. Date: 2011-07-27

Inventor: STEHNO-BITTEL LISA A [US]; RAMACHANDRAN KARTHIK [US]


Publication No.: WO2013016656A1  Published: 31/Jan/2013

Title: SANDALWOOD OIL AND ITS USES RELATED TO SKIN DISORDERS

Applicant/Assignee: SANTALIS PHARMACEUTICALS INC

Application No.: WO2012US48599 (PCT/US2012/48599)   Filing Date: 27/Jul/2012

Abstract:

Provided herein are compositions of sandalwood heartwood oil and methods of making and using such compositions.

Priority: US201161512647P Applic. Date: 2011-07-28; US201261608279P Applic. Date: 2012-03-08

Inventor: CLEMENTS IAN [US]; CASTELLA PAUL [US]; LEVENSON COREY [US]


Publication No.: WO2013016718A1  Published: 31/Jan/2013

Title: COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES

Applicant/Assignee: CELLWORKS RESEARCH INDIA PRIVATE LIMITED, CELLWORKS GROUP, INC

Application No.: WO2012US48739 (PCT/US2012/48739)   Filing Date: 27/Jul/2012

Abstract:

The present invention describes a composition and a kit, each having a plurality of compounds, for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as Rheumatoid Arthritis (RA).The invention also relates to a process of obtaining the composition and a method of treating diseases by administration of the compositions.

Priority: IN2011CH02591 Applic. Date: 2011-07-28

Inventor: VALI SHIREEN [IN]; VIDVA ROBINSON [IN]; NAIR PRASHANT RAMACHANDRAN [IN]; FERNANDES PRADEEP [US]; ABBASI TAHER [US]; RADHAKRISHNAN SAUMYA [IN]


Publication No.: WO2013016720A2  Published: 31/Jan/2013

Title: NOVEL SUBSTITUTED BIARYLHETEROCYCLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES

Applicant/Assignee: GERINDA THERAPEUTICS, INC

Application No.: WO2012US48741 (PCT/US2012/48741)   Filing Date: 28/Jul/2012

Abstract:

The present invention provides a new patentable class of substituted benzoxazole derivative compounds that exhibit protein kinase (PK) inhibition activity or modulating ability, as well as compositions and methods of using such compounds, for example, to prevent or treat various diseases and disorders in human and non-human animals.

Priority: US201161512882P Applic. Date: 2011-07-28

Inventor: PFAHL MAGNUS [US]; PIEDRAFITA F JAVIER [US]; VENKAT LAXMAN RAO CILAMKOTI [IN]; VEERAMANENI VENUGOPAL RAO [IN]; VENEPALLI BHASKAR [US]


Publication No.: WO2013017233A1  Published: 07/Feb/2013

Title: INTRATHECAL OR EPIDURAL ADMINISTRATION OF 3-[(1S,2S)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL]PHENOL

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: WO2012EP03186 (PCT/EP2012/03186)   Filing Date: 27/Jul/2012

Abstract:

The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any peripherally or supraspinally mediated side effect in the subject. In particular, the present invention relates to a method of administering 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes.

Priority: US201161513163P Applic. Date: 2011-07-29

Inventor: BLOMS-FUNKE PETRA [DE]; SAUNDERS DEREK JOHN [DE]; LANG ERIC [US]


Publication No.: WO2013017494A1  Published: 07/Feb/2013

Title: PHARMACEUTICAL COMPOSITION OF OXIDISED AVIDIN SUITABLE FOR INHALATION

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A

Application No.: WO2012EP64576 (PCT/EP2012/64576)   Filing Date: 25/Jul/2012

Abstract:

The present invention describes oxidized avidin, suitable for inhalation, for conditioning the lung affected by inoperable/diffuse diseases, enabling the targeted delivery of biotinylated therapeutic agents to it.

Priority: EP20110006338 Applic. Date: 2011-08-02

Inventor: DE SANTIS RITA [IT]


Publication No.: WO2013017571A1  Published: 07/Feb/2013

Title: AQUEOUS SOLUTIONS OF LIPOPHILIC SUBSTANCES, IN PARTICULAR MEDICINAL SOLUTIONS

Applicant/Assignee: UNIVERSITAET REGENSBURG

Application No.: WO2012EP64895 (PCT/EP2012/64895)   Filing Date: 30/Jul/2012

Abstract:

The invention relates to aqueous solutions, containing at least one lipophilic substance and, as a solubilizer for the at least one lipophilic substance, a surfactant selected from the group of polyoxyethylene fatty alcohol ethers and derivatives thereof, polyoxyethylene fatty acid esters and derivatives thereof, phospholipids and derivatives thereof, and cationic surfactants. The invention further relates to the use of the aqueous solution, in particular for producing a drug for oral, parenteral, topical, or ophthalmic administration.

Priority: DE201110108948 Applic. Date: 2011-07-29

Inventor: LUSCHMANN CHRISTOPH [DE]; GOEPFERICH ACHIM [DE]


Publication No.: WO2013017807A1  Published: 07/Feb/2013

Title: ANTISEPTIC COMPOSITION

Applicant/Assignee: PETCARE INNOVATION

Application No.: WO2012FR51838 (PCT/FR2012/51838)   Filing Date: 02/Aug/2012

Abstract:

The invention relates to an antiseptic composition. The composition comprises an association of at least silver metal, preferably in a micronised form, and hyaluronic acid or one of the salts thereof having a molecular weight of between 50 kDa and 2000 kDa. The invention can be especially applied to the field of veterinary medicine, for the treatment of skin wounds and the healing thereof.

Priority: FR20110057144 Applic. Date: 2011-08-04

Inventor: ALLART JEAN-CLAUDE [FR]; LEFEVRE JEAN-MARIE [FR]; PEYROT JACQUES [FR]


Publication No.: WO2013017808A1  Published: 07/Feb/2013

Title: ANTISEPTIC COMPOSITION

Applicant/Assignee: DERMACONCEPT JMC

Application No.: WO2012FR51839 (PCT/FR2012/51839)   Filing Date: 02/Aug/2012

Abstract:

The invention relates to an antiseptic composition. The composition comprises an association of at least silver metal, preferably in a micronised form, and hyaluronic acid or one of the salts thereof having a molecular weight of between 50 kDa and 2000 kDa. The invention can be especially applied to the fields of ophthalmology and dermatology, for the treatment of skin wounds.

Priority: FR20120054411 Applic. Date: 2012-05-15; FR20110057144 Applic. Date: 2011-08-04

Inventor: ALLART JEAN-CLAUDE [FR]; LEFEVRE JEAN-MARIE [FR]; PEYROT JACQUES [FR]


Publication No.: WO2013017821A1  Published: 07/Feb/2013

Title: PHARMACEUTICAL COMPOSITION COMPRISING EBASTINE AND FLUTICASONE

Applicant/Assignee: CIPLA LIMITED, KING, LAWRENCE

Application No.: WO2012GB00631 (PCT/GB2012/00631)   Filing Date: 02/Aug/2012

Abstract:

A pharmaceutical composition comprises at least one antihistamine, at least one corticosteroid, and at least one pharmaceutical excipient, wherein the at least one antihistamine comprises ebastine or its pharmaceutically acceptable salt, solvate, ester or physiologically functional derivative thereof, and wherein the at least one corticosteroid comprises fluticasone or its pharmaceutically acceptable ester thereof.

Priority: IN2011MU02193 Applic. Date: 2011-08-02

Inventor: MALHOTRA GEENA [IN]; PURANDARE SHRIVINAS [IN]


Publication No.: WO2013017928A1  Published: 07/Feb/2013

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS

Applicant/Assignee: ALFA WASSERMANN S.P.A

Application No.: WO2012IB01438 (PCT/IB2012/01438)   Filing Date: 26/Jul/2012

Abstract:

The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.

Priority: IT2011BO00461 Applic. Date: 2011-07-29

Inventor: VISCOMI GIUSEPPE CLAUDIO [IT]; MAFFEI PAOLA [IT]; LAURO VITTORIA [IT]; CALANNI FIORELLA [IT]; VITALI BEATRICE [IT]; CRUCIANI FEDERICA [IT]


Publication No.: WO2013018008A1  Published: 07/Feb/2013

Title: BASIC ALPHA LIPOIC ACID SOLUTION AND ITS USES

Applicant/Assignee: ISTITUTO BIOCHIMICO NAZIONALE SAVIO S.R.L

Application No.: WO2012IB53840 (PCT/IB2012/53840)   Filing Date: 27/Jul/2012

Abstract:

A solution is disclosed having a pH 7.0 to 9.5, comprising alpha lipoic acid or its enantiomer, an inorganic compound and a solvent, said solvent being a mixture of water and a polyol. Said solution presents high stability of the alpha lipoic acid over time, as well as high edibility and bioavailability.

Priority: IT2011MI01452 Applic. Date: 2011-07-29

Inventor: BRUFANI MARIO [IT]; FIGLIOLA ROCCO [IT]; LAGRASTA BIANCA MARIA [IT]; MARZELLA ROLANDO [IT]; MEDICI ILARIA [IT]; SILVESTRI SILVIO [IT]


Publication No.: WO2013018017A1  Published: 07/Feb/2013

Title: ANTITUMOUR COMBINATION COMPRISING OMBRABULIN AND CISPLATIN, ASSOCIATED WITH RADIOTHERAPY

Applicant/Assignee: SANOFI

Application No.: WO2012IB53879 (PCT/IB2012/53879)   Filing Date: 30/Jul/2012

Abstract:

The invention relates to an antitumour pharmaceutical combination comprising ombrabulin or AVE8062, which may be in the form of a base or in the form of a pharmaceutically acceptable salt, and cisplatin, for use thereof as an antitumour agent intended for patients who are also treated with radiotherapy, in particular suffering from cancers and even more particularly suffering from solid tumours.

Priority: FR20110057040 Applic. Date: 2011-08-01

Inventor: CARREZ CHANTAL [FR]; CLEMENSON CELINE [FR]; DEUTSCH ERIC [FR]


Publication No.: WO2013018018A1  Published: 07/Feb/2013

Title: ANTITUMOUR COMBINATION COMPRISING OMBRABULIN AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY

Applicant/Assignee: SANOFI

Application No.: WO2012IB53881 (PCT/IB2012/53881)   Filing Date: 30/Jul/2012

Abstract:

The invention relates to an antitumour pharmaceutical combination comprising ombrabulin or AVE8062, which may be in the form of a base or in the form of a pharmaceutically acceptable salt, and cisplatin, for use thereof as an antitumour agent intended for patients who are also treated with radiotherapy, in particular suffering from cancers and even more particularly suffering from solid tumours.

Priority: FR20110057044 Applic. Date: 2011-08-01

Inventor: CARREZ CHANTAL [FR]; CLEMENSON CELINE [FR]; DEUTSCH ERIC [FR]


Publication No.: WO2013018035A1  Published: 07/Feb/2013

Title: PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VII ENCAPSULATED IN MICELLES

Applicant/Assignee: LFB BIOTECHNOLOGIES, NANOCARRIER CO., LTD

Application No.: WO2012IB53914 (PCT/IB2012/53914)   Filing Date: 31/Jul/2012

Abstract:

The invention relates to a pharmaceutical composition comprising factor VII encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the goup consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.

Priority: EP20110176276 Applic. Date: 2011-08-02

Inventor: ARVIS FLORENCE [FR]; HUILLE SYLVAIN [FR]; HARADA MITSUNORI [JP]


Publication No.: WO2013018695A1  Published: 07/Feb/2013

Title: HETEROCYCLIC COMPOUND

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: WO2012JP69138 (PCT/JP2012/69138)   Filing Date: 27/Jul/2012

Abstract:

To provide a heterocyclic compound which has an ROR?t inhibitory effect. A compound represented by formula (I) or a salt thereof. (In the formula, ring A represents an optionally substituted cyclic group

Q represents a bonding hand or the like

R1 represents a substituent

ring B represents a thiazole ring, an isothiazole ring or a dihydrothiazole ring, each of which can be additionally substituted by a substituent other than R2

and R2 represents an optionally substituted aminocarbonyl-C1-6 alkyl group or the like.)

Priority: JP20110167693 Applic. Date: 2011-07-29

Inventor: YAMAMOTO SATOSHI [JP]; SHIRAI JUNYA [JP]; OCHIDA ATSUKO [JP]; FUKASE YOSHIYUKI [JP]; TOMATA YOSHIHIDE [JP]; SATO AYUMU [JP]; MIURA SHOTARO [JP]; YONEMORI KAZUKO [JP]; KOYAMA RYOKICHI [JP]


Publication No.: WO2013018733A1  Published: 07/Feb/2013

Title: 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: WO2012JP69246 (PCT/JP2012/69246)   Filing Date: 27/Jul/2012

Abstract:

A 1,5-naphthyridine derivative represented by general formula [1] (wherein each of R1, R2, R3, R4 and R5 represents a hydrogen atom, an -L-Z group (wherein Z represents a non-aromatic heterocyclic group or the like, and L represents a single bond or the like) or the like

R6 represents an -L-Z group or the like

each of R7 and R8 represents a hydrogen atom or the like

and Q represents an oxygen atom or the like) or a salt thereof has excellent inhibitory activity against the PI3K-AKT pathway and the Ras-Raf-MEK-ERK pathway, and is useful for the prophylaxis or treatment of diseases associated with the PI3K-AKT pathway and the Ras-Raf-MEK-ERK pathway.

Priority: JP20110167489 Applic. Date: 2011-07-29

Inventor: FURUYAMA HIDETOMO [JP]; KURIHARA HIDEKI [JP]; FURUYA KENTAROU [JP]; TERAO TAKAHIRO [JP]; SEKINE SHINICHIROU [JP]; NAKAGAWA DAISUKE [JP]


Publication No.: WO2013018779A1  Published: 07/Feb/2013

Title: CRYSTAL OF a-GLUCOSYL HESPERIDIN AND USE THEREOF

Applicant/Assignee: HAYASHIBARA CO., LTD

Application No.: WO2012JP69378 (PCT/JP2012/69378)   Filing Date: 30/Jul/2012

Abstract:

The purpose of the present invention is to provide: a novel crystal of a-glucosyl hesperidin, of which the crystal structure is elucidated

a powder substantially comprising the crystal

and use of the powder as a material for a medicinal agent. The purpose can be achieved by providing: a crystal of a-glucosyl hesperidin, which has a crystallographic space group of P21, and of which the unit lattice has a lattice constant a of 13.983 AA, a lattice constant b of 7.620 AA and a lattice constant c of 20.065 AA, and which is a monoclinic crystal wherein a = ? = 90 DEG and ss = 93.475 DEG

a powder substantially comprising the crystal

and use of the powder as a material for a medicinal agent.

Priority: JP20110168720 Applic. Date: 2011-08-01

Inventor: SHIBUYA TAKASHI [JP]; IZAWA SEISUKE [JP]


Publication No.: WO2013018805A1  Published: 07/Feb/2013

Title: FRAGRANCE FOR SUPPRESSING FECAL ODOR, MICROCAPSULATED FRAGRANCE USING SAME, TEXTILE HAVING FECAL ODOR SUPPRESSING CAPABILITY, PELLET FOR SUPPRESSING FECAL ODOR, MICROCAPSULATED FRAGRANCE MISTING SPRAY, AND SPRAY FOR SUPPRESSING FECAL ODOR

Applicant/Assignee: YAMAMOTO PERFUMERY CO., LTD, SHIBATA CORPORATION

Application No.: WO2012JP69489 (PCT/JP2012/69489)   Filing Date: 31/Jul/2012

Abstract:

Provided is a fragrance for suppressing fecal odors which enables, when fecal odors are smelled, fecal odors to be incorporated as a component of the fragrance and converted into a high-grade scent, which can not be achieved with conventional aromatic agents or the like. Furthermore, the composition of the formulation for the fragrance is simple. The fragrance is prepared following a differential formulation in which only the emphasizing perfume component is removed from a target formulation for a plant-based body fragrance comprising: a keynote perfume component having a floral-based scent

a modulation perfume component comprising an animal perfume having an animal odor- or fat-based scent and that modulates the floral-based scent based on the keynote perfume component so as to blend with the scent of human skin, forming a modulated plant-based scent

and the aforementioned emphasizing perfume component comprising an animal perfume having a fecal odor and that emphasizes and causes the modulated plant-based scent to smell stronger. While the smell from the modulated plant-based scent alone is weaker than the plant-based body fragrance according the target formulation, when a fecal odor is overlapped with the modulated plant-based scent, the fecal odor is incorporated as a substitution component for the emphasizing perfume component, and the smell from the modulated plant-based scent is emphasized.

Priority: JP20110179236 Applic. Date: 2011-08-01; JP20120018778 Applic. Date: 2012-01-31; JP20120031316 Applic. Date: 2012-02-16

Inventor: YAMAMOTO YOSHIKUNI [JP]; TOZUKA SEIJI [JP]


Publication No.: WO2013018837A1  Published: 07/Feb/2013

Title: LEFT VENTRICULAR DIASTOLIC FUNCTION IMPROVING AGENT

Applicant/Assignee: ONO PHARMACEUTICAL CO., LTD

Application No.: WO2012JP69609 (PCT/JP2012/69609)   Filing Date: 01/Aug/2012

Abstract:

Provided is a therapeutic agent for heart failure, which can improve the diastolic function of the left ventricle without relying on the diuretic activity or the vasodilatory activity thereof and therefore can control the condition of impaired vasodilatation so as to prevent the recurrence of impaired vasodilatation, and can also improve breathing difficulty or death associated with the condition of impaired vasodilatation. 4-[(2-{(2R)-2-[(1E,3S)-4-(4-Fluorophenyl)-3-hydroxy-1- butene-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid can act on the heart directly to improve the diastolic function of the left ventricle, and therefore can treat heart failure, particularly impaired vasodilatation, effectively. Thus, the present invention can provide a novel therapeutic agent for heart failure, which can improve impaired vasodilatation for which any effective treatment method is not established yet.

Priority: JP20110169389 Applic. Date: 2011-08-02

Inventor: KANAJI TOSHIYA [JP]; FUCHIBE KAZUHIRO [JP]; TAKAHASHI MASAYA [JP]


Publication No.: WO2013019137A1  Published: 07/Feb/2013

Title: OXIDE FERRIMAGNETICS WITH SPINEL STRUCTURE NANOPARTICLES AND IRON OXIDE NANOPARTICLES, BIOCOMPATIBLE AQUEOUS COLLOIDAL SYSTEMS COMPRISING NANOPARTICLES, FERRILIPOSOMES, AND USES THEREOF

Applicant/Assignee: INSTITUTION OF THE RUSSIAN ACADEMY OF SCIENCES TOMSK SCIENTIFIC CENTER, SIBERIAN BRANCH, RUSSIAN ACA, JOZEF STEFAN INSTITUTE

Application No.: WO2011RU00574 (PCT/RU2011/00574)   Filing Date: 04/Aug/2011

Abstract:

The present invention relates to methods for producing oxide ferrimagnetics with spinel structure and iron oxide nanoparticles by mechanochemical synthesis, oxide ferrimagnetics with spinel structure and iron oxide nanoparticles of ultra small size and high specific surface area obtainable by the methods, biocompatible aqueous colloidal systems comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, ferriliposomes comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, and uses thereof in medicine.

Priority: WO2011RU00574 Applic. Date: 2011-08-04

Inventor: VASILJEVA OLGA [SI]; ITIN VOLYA ISAEVICH [RU]; PSAKHIE SERGEY GRIGORIEVICH [RU]; MIKHAYLOV GEORGY ANDREEVICH [SI]; MIKAC MOJCA URSKA [SI]; TURK BORIS [SI]; MAGAEVA ANNA ALEKSEEVNA [RU]; NAIDEN EVGENIY PETROVICH [RU]; TEREKHOVA OLGA GEORGIEVNA [RU]


Publication No.: WO2013019169A1  Published: 07/Feb/2013

Title: PHOSPHATE PRODRUGS

Applicant/Assignee: INSTITUTE FOR ONEWORLD HEALTH

Application No.: WO2011US01359 (PCT/US2011/01359)   Filing Date: 01/Aug/2011

Abstract:

Phosphate and phosphonate prodrug derivatives, for example of Formula IV

where p, A, LA, and R1, R3-R6 are as defined herein, are useful for treating various disorders, including diarrhea.

Priority: WO2011US01359 Applic. Date: 2011-08-01

Inventor: NGUYEN TUE [US]; DE HOSTOS EUGENIO [US]


Publication No.: WO2013019220A1  Published: 07/Feb/2013

Title: COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME

Applicant/Assignee: TELIK, INC

Application No.: WO2011US46316 (PCT/US2011/46316)   Filing Date: 02/Aug/2011

Abstract:

This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof in patients who have been treated with a DNA methyltransferase inhibitor by a combination of ezatiostat or a salt thereof and lenalidomide.

Priority: WO2011US46316 Applic. Date: 2011-08-02

Inventor: BROWN GAIL L [US]; MENG LIXIN [US]


Publication No.: WO2013019221A1  Published: 07/Feb/2013

Title: COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME

Applicant/Assignee: TELIK, INC

Application No.: WO2011US46317 (PCT/US2011/46317)   Filing Date: 02/Aug/2011

Abstract:

This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide.

Priority: WO2011US46317 Applic. Date: 2011-08-02

Inventor: BROWN GAIL L [US]; MENG LIXIN [US]


Publication No.: WO2013019222A1  Published: 07/Feb/2013

Title: COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME

Applicant/Assignee: TELIK, INC

Application No.: WO2011US46319 (PCT/US2011/46319)   Filing Date: 02/Aug/2011

Abstract:

This invention relates to specific treatment regimens for treating myelodysplasia syndrome.

Priority: WO2011US46319 Applic. Date: 2011-08-02

Inventor: BROWN GAIL L [US]


Publication No.: WO2013019805A1  Published: 07/Feb/2013

Title: TREATMENT OF HEART FAILURE AND RELATED CONDITIONS

Applicant/Assignee: TUFTS MEDICAL CENTER, INC

Application No.: WO2012US49018 (PCT/US2012/49018)   Filing Date: 31/Jul/2012

Abstract:

Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGFss1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGFss1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGFss1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin.

Priority: US201161513930P Applic. Date: 2011-08-01; US201161578477P Applic. Date: 2011-12-21

Inventor: KAPUR NAVIN K [US]; KARAS RICHARD H [US]


Publication No.: WO2013020021A1  Published: 07/Feb/2013

Title: STABLE ANTI-INFLAMMATORY SOLUTIONS FOR INJECTION

Applicant/Assignee: OMEROS CORPORATION

Application No.: WO2012US49463 (PCT/US2012/49463)   Filing Date: 03/Aug/2012

Abstract:

The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline.

Priority: US201161515234P Applic. Date: 2011-08-04

Inventor: DEMOPULOS GREGORY A [US]; GOMBOTZ WAYNE R [US]; SHEN HUI-RONG [US]


Publication No.: WO2013020527A1  Published: 14/Feb/2013

Title: UTILIZATION OF ALAPTIDE AS TRANSDERMAL PENETRATION MODIFIER IN PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND VETERINARY APPLICATIONS CONTAINING ANTI-INFLAMMATORY DRUGS AND/OR ANTIMICROBIAL CHEMOTHERAPEUTICS

Applicant/Assignee: UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES BRNO FACULTY OF PHARMACY

Application No.: WO2012CZ00073 (PCT/CZ2012/00073)   Filing Date: 02/Aug/2012

Abstract:

The invention deals with the way of utilization of micronized, nanonized and/or surface-modified alaptide, which affects penetration of other pharmaceutically active compounds through the skin as a pharmaceutical adjuvant (excipient). These pharmaceutical compositions composed of alaptide as the excipient, pharmaceutical active ingredients (non-steroidal anti-inflammatory drugs and/or antipyretics/non-opiate analgesics and/or glucocorticoids and/or antimicrobial chemotherapeutics, i.e. antibacterials, antimycotics, antivirotics) and other pharmaceutical excipients can be used for preparation of drug formulations, which can influence the drug level in the body in time and can be used for both local and systemic administration.

Priority: CZ20110000495 Applic. Date: 2011-08-11; CZ20120000072 Applic. Date: 2012-02-01; CZ20120000511 Applic. Date: 2012-07-26

Inventor: JAMPILEK JOSEF [CZ]; OPATRILOVA RADKA [CZ]; COUFALOVA LENKA [CZ]; CERNIKOVA ANETA [CZ]; DOHNAL JIRI [CZ]


Publication No.: WO2013020774A1  Published: 14/Feb/2013

Title: VIOLET LEAVES ODORANTS

Applicant/Assignee: FIRMENICH SA

Application No.: WO2012EP63765 (PCT/EP2012/63765)   Filing Date: 13/Jul/2012

Abstract:

The present invention relates to the use as perfuming ingredient of a compound of formula in the form of any one of its stereoisomers or a mixture thereof, and wherein each R1 represents a hydrogen atom or a methyl group and at least one of said R1 is a hydrogen atom

R2 represents a linear or branched C3-8 alkyl group or unsaturated groups

and R3 represents a hydrogen atom or a methyl group

in particular to impart odor notes of the violet leaves type optionally together with green odor notes.

Priority: EP20110177220 Applic. Date: 2011-08-11

Inventor: CHAPUIS CHRISTIAN [CH]


Publication No.: WO2013020917A1  Published: 14/Feb/2013

Title: Ophthalmologic composition comprising an aqueous solution of at least one viscoelastic polysaccharide

Applicant/Assignee: CARL ZEISS MEDITEC AG

Application No.: WO2012EP65248 (PCT/EP2012/65248)   Filing Date: 03/Aug/2012

Abstract:

The invention relates to an ophthalmologic composition, comprising an aqueous solution of at least one viscoelastic polysaccharide, wherein the at least one polysaccharide is covalently bound to at least one dye. The invention also relates to a method for producing an ophthalmologic composition, in which at least one dye is covalently bound to at least one water-soluble, viscoelastic polysaccharide.

Priority: GB20110014317 Applic. Date: 2011-08-09

Inventor: NACHBAUR JUERGEN [DE]; RODDEN GILLIAN DR [GB]; WOLFSTEIN ANDRE DR [DE]; MOISSONNIER CLAUDE [DE]; BERNARD PASCAL [FR]; LOREC GILDAS [FR]; BIELEFELDT NICOLE [DE]; RATHERT BRIAN [DE]; NACHBAUR LIDIA DR [DE]; GERLACH MARIO [DE]


Publication No.: WO2013021139A1  Published: 14/Feb/2013

Title: SOLID PHARMACEUTICAL COMPOSITION FOR ORALLY DELIVERING AGOMELATINE

Applicant/Assignee: LES LABORATOIRES SERVIER

Application No.: WO2012FR51874 (PCT/FR2012/51874)   Filing Date: 09/Aug/2012

Abstract:

The invention relates to a solid oral pharmaceutical composition containing agomelatine for systemic action.

Priority: FR20110002500 Applic. Date: 2011-08-10

Inventor: THARRAULT FRANCOIS [FR]; POIRIER CECILE [FR]; FONKNECHTEN GILLES [FR]; PEAN JEAN-MANUEL [FR]


Publication No.: WO2013021143A1  Published: 14/Feb/2013

Title: INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN

Applicant/Assignee: ADOCIA

Application No.: WO2012FR51880 (PCT/FR2012/51880)   Filing Date: 09/Aug/2012

Abstract:

The invention relates to an injectable solution having a pH of 7, and including at least one type of basal insulin, the pI of which is between 5.8 and 8.5. The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least: a) one type of basal insulin, the isoelectric point (pI) of which is between 5.8 and 8.5

and b) a dextran substituted with radicals having carboxylate fillers and hydrophobic radicals of formula I or II, where R is -OH or is selected from the group consisting of the radicals o-(f-[A]-COOH), o-(g-[B]-k-[D])m, D comprising at least one alkyl chain comprising at least 8 carbon atoms, where R is -OH or a radical -(f-[A]-COOH)n, and R' is selected from the group consisting of the radicals o-CH2NH-[E](-o-[F])t and o-C(O)NH-[E](-o-[F])t.

Priority: FR20110057291 Applic. Date: 2011-08-10; US201161522031P Applic. Date: 2011-08-10; FR20110062445 Applic. Date: 2011-12-23; US201161579966P Applic. Date: 2011-12-23

Inventor: SOULA OLIVIER [FR]; SOULA GERARD [FR]; TONNAR JEFF [FR]; GEISSLER ALEXANDRE [FR]


Publication No.: WO2013021199A2  Published: 14/Feb/2013

Title: PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: PROSONIX LIMITED

Application No.: WO2012GB51924 (PCT/GB2012/51924)   Filing Date: 08/Aug/2012

Abstract:

This invention provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for delivery to the lung by inhalation. This invention also provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for the treatment of respiratory disease.

Priority: GB20110013662 Applic. Date: 2011-08-08

Inventor: RUECROFT GRAHAM [GB]; PARIKH DIPESH [GB]


Publication No.: WO2013021249A1  Published: 14/Feb/2013

Title: DEGRADATION-RESISTANT CROSS-LINKED, LOW-MOLECULAR-WEIGHT HYALURONATE

Applicant/Assignee: GLYCORES 2000 S.R.L

Application No.: WO2012IB01472 (PCT/IB2012/01472)   Filing Date: 31/Jul/2012

Abstract:

There is described a biodegradable but degradation-resistant product consisting of a new cross-linked, low-molecular-weight hyaluronic acid semisolid, clear hydrogel derived from a sodium hyaluronate substrate having a molecular weight of from 50,000 to 100,000 Da. The product has a high resistance to enzymatic degradation and is for use in biomedical, pharmaceutical and cosmetic applications.

Priority: EP20110006559 Applic. Date: 2011-08-10

Inventor: ORESTE PASQUA ANNA [IT]


Publication No.: WO2013021302A1  Published: 14/Feb/2013

Title: ANTI-OXIDANT HERBAL COMPOSITION

Applicant/Assignee:

Application No.: WO2012IB53809 (PCT/IB2012/53809)   Filing Date: 26/Jul/2012

Abstract:

An anti-oxidant herbal composition comprising Termanalia arjuna extract, Camellia sinensis extract, and Trikatu extract in specific weight percentages and optionally at least one carrier. Use of the composition for treatment and/or prevention of hyperlipidemia and/or ischemic heart disease and a method of preparation of the composition are also provided.

Priority: IN2011MU02240 Applic. Date: 2011-08-09

Inventor: SHUKLA MUKESH HARILAL [IN]; TRIVEDI MITESH PRADIPKUMAR [IN]


Publication No.: WO2013022410A2  Published: 14/Feb/2013

Title: PRODUCTION METHOD FOR EFFERVESCENT FORMULATIONS COMPRISING DEXKETOPROFEN

Applicant/Assignee:

Application No.: WO2012TR00130 (PCT/TR2012/00130)   Filing Date: 08/Aug/2012

Abstract:

The present invention relates to aproduction method used for production of effervescent formulations comprising dexketoprofen and the effervescent formulations obtained by this method.

Priority: TR20110007834 Applic. Date: 2011-08-08

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2013022982A2  Published: 14/Feb/2013

Title: PEGYLATED TYROSYL-TRNA SYNTHETASE POLYPEPTIDES

Applicant/Assignee: ATYR PHARMA, INC

Application No.: WO2012US50012 (PCT/US2012/50012)   Filing Date: 08/Aug/2012

Abstract:

The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.

Priority: US201161521696P Applic. Date: 2011-08-09

Inventor: WATKINS JEFFRY D [US]; BUECHLER YING JI [US]; WU CHI-FANG [US]; DO MINH-HA [US]; VASSEROT ALAIN P [US]; MENDLEIN JOHN D [US]


Publication No.: WO2013023439A1  Published: 21/Feb/2013

Title: SALT AND POLYMORPH OF PYRAZOLOPYRIMIDINONE COMPOUND AND DRUG COMPOSITION, PREPARATION METHOD AND USE THEREOF

Applicant/Assignee: TOPHARMAN SHANGHAI CO., LTD, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, TOPHARMAN SHANDONG CO., LTD

Application No.: WO2012CN01082 (PCT/CN2012/01082)   Filing Date: 14/Aug/2012

Abstract:

The present invention relates to salts and a pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystal, anhydride or amorphous form of a novel pyrazolopyrimidinone compound as shown in general formula (I), and to a pharmaceutical composition and a pharmaceutical unit dosage form comprising same, wherein X represents an organic or inorganic acid, preferably maleic acid, succinic acid, hydrochloric acid, methylsulfonic acid and the like. The present invention further relates to a co-crystal or a composite of the pyrazolopyrimidinone compound, and a pharmaceutical composition comprising same. The present invention also relates to a preparation method of the abovementioned substances, and the use thereof and pharmaceutical preparations comprising these salts and crystal forms.

Priority: CN20111236585 Applic. Date: 2011-08-17

Inventor: LI JIANFENG [CN]; TIAN GUANGHUI [CN]; WANG ZHEN [CN]; SUO JIN [CN]; JIANG XIANGRUI [CN]; LIU ZHENG [CN]; YANG XIAOJUN [CN]; XIE ZHU [CN]; ZHAO XIANGUO [CN]; ZHU WEILIANG [CN]; JIANG HUALIANG [CN]; SHEN JINGSHAN [CN]


Publication No.: WO2013023511A1  Published: 21/Feb/2013

Title: TRIAZOLOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF

Applicant/Assignee: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD, JIANGSU HENGRUI MEDICINE CO., LTD

Application No.: WO2012CN78798 (PCT/CN2012/78798)   Filing Date: 18/Jul/2012

Abstract:

The present invention relates to triazolopyrimidine derivatives and a preparation method and a use thereof. In particular, the present invention relates to triazolopyrimidine derivatives as shown in general formula (I), and the use thereof as a therapeutic agent, especially as a P2Y12 receptor antagonist, wherein the definition of each substituent in general formula (I) is the same as the definition in the description.

Priority: CN20111235135 Applic. Date: 2011-08-12; CN20111370521 Applic. Date: 2011-11-21

Inventor: TU WANGYANG [CN]; FAN JIANG [CN]; ZHANG HAITANG [CN]; XU GUOJI [CN]; LIU ZHIWEI [CN]; QU JIAN [CN]; YANG FANGLONG [CN]; DONG QING [CN]; SUN PIAOYANG [CN]


Publication No.: WO2013023775A1  Published: 21/Feb/2013

Title: ORODISPERSIBLE FILMS FOR THE MANUFACTURING OF INDIVIDUALISED MEDICINE OR FOR LARGE SCALE PRODUCTION

Applicant/Assignee: LABTEC GMBH

Application No.: WO2012EP03446 (PCT/EP2012/03446)   Filing Date: 13/Aug/2012

Abstract:

The present invention pertains to oral applicable therapeutic dosage forms, in particular to orodispersible films. The present invention especially is directed to orodispersible films comprising a base layer substantially free of therapeutically active agents and a top layer comprising the desired therapeutically active agents. The present invention also concerns suitable base layers for such orodispersible films as well as therapeutical uses thereof and methods for manufacturing them.

Priority: DE20111080870 Applic. Date: 2011-08-12; DE20111088909 Applic. Date: 2011-12-16; EP20110189610 Applic. Date: 2011-11-17

Inventor: BREITENBACH ARMIN [DE]; BRAUN SEBASTIAN [DE]; SCHLIEPHACKE RALF [DE]


Publication No.: WO2013023841A1  Published: 21/Feb/2013

Title: METHOD FOR PRODUCING AND MONITORING ORAL ACTIVE INGREDIENT FILMS

Applicant/Assignee: TESA SE, LABTEC GMBH

Application No.: WO2012EP63405 (PCT/EP2012/63405)   Filing Date: 09/Jul/2012

Abstract:

Method for producing and monitoring oral active ingredient films with a base to which a solution containing at least one active ingredient is applied, the method comprising the steps: DEG metering and mixing the base formulation, DEG coating the base formulation onto a substrate, so that a strip results DEG if necessary, drying the base formulation strip coated on the substrate DEG printing a colorant solution containing at least one active ingredient onto the upper side of the base formulation strip according to the flexographic printing method, DEG drying the base formulation strip coated on the substrate together with the printed active ingredient solution, DEG penetrating the base formulation strip coated on the substrate together with the printed active ingredient solution from the upper and/or lower side by means of radiation from a radiation source, DEG measuring the transmission of the penetrating radiation by means of at least one reception unit on the opposite side of the base formulation strip coated on the substrate together with the printed active ingredient solution.

Priority: DE20111080870 Applic. Date: 2011-08-12; DE20111088909 Applic. Date: 2011-12-16

Inventor: BRAUN SEBASTIAN [DE]; BREITENBACH ARMIN [DE]; SCHLIEPHACKE RALF [DE]


Publication No.: WO2013023856A1  Published: 21/Feb/2013

Title: USE OF A POLYSACCHARIDE POLYMER FROM THE SEEDS OF THE TAMARIND SEED IN PROTECTING AGAINST TOBACCO-ASSOCIATED DAMAGES

Applicant/Assignee: ZAMBON S.P.A

Application No.: WO2012EP63975 (PCT/EP2012/63975)   Filing Date: 17/Jul/2012

Abstract:

Use of a polysaccharide polymer obtained from the seeds of the tamarind tree for use in protecting the epithelial cells of the respiratory tract by damages induced by tobacco smoke.

Priority: EP20110006634 Applic. Date: 2011-08-12

Inventor: SARDINA MARCO [IT]; ALETTI ADONELLA [IT]; MELLONI ELSA [IT]


Publication No.: WO2013023882A1  Published: 21/Feb/2013

Title: URIDINE AND URIDINE ANALOGUES FOR TREATMENT OF SPECIFIC LUNG DISEASES, NAMELY COPD AND PULMONARY FIBROSIS

Applicant/Assignee: UNIVERSITAETSKLINIKUM FREIBURG

Application No.: WO2012EP64481 (PCT/EP2012/64481)   Filing Date: 24/Jul/2012

Abstract:

The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogues.

Priority: EP20110177357 Applic. Date: 2011-08-12

Inventor: IDZKO MARCO [DE]; SORICHTER STEPHAN [DE]


Publication No.: WO2013024002A1  Published: 21/Feb/2013

Title: PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: WO2012EP65643 (PCT/EP2012/65643)   Filing Date: 10/Aug/2012

Abstract:

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Priority: US201161522857P Applic. Date: 2011-08-12

Inventor: DO STEVEN [US]; HU HUIYONG [US]; KOLESNIKOV ALEKSANDR [US]; LEE WENDY [US]; TSUI VICKIE HSIAO-WEI [US]; WANG XIAOJING [US]; WEN ZHAOYANG [US]


Publication No.: WO2013024023A1  Published: 21/Feb/2013

Title: TASTE MASKED PHARMACEUTICAL COMPOSITION

Applicant/Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH

Application No.: WO2012EP65680 (PCT/EP2012/65680)   Filing Date: 10/Aug/2012

Abstract:

This application relates to taste masked multi-layered particles comprising a pharmaceutically active ingredient, comprising: (a) an inert core, (b) one or more coating layer(s) comprising the pharmaceutically active ingredient and a binder, (c) an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound, comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP and (d) an outer coating layer (final or taste masking coating) free from a low molecular weight water- soluble ionic compound comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water- soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.

Priority: EP20110177354 Applic. Date: 2011-08-12

Inventor: FOLGER MARTIN [DE]; LEHNER STEFAN [DE]; GRAVE ANNETTE [DE]; POELLINGER NORBERT [DE]; SEIDLER RANDOLPH [DE]


Publication No.: WO2013024036A1  Published: 21/Feb/2013

Title: FUNNY CURRENT (IF) INHIBITORS FOR USE IN A METHOD OF TREATING AND PREVENTING HEART FAILURE IN FELINE

Applicant/Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH

Application No.: WO2012EP65704 (PCT/EP2012/65704)   Filing Date: 10/Aug/2012

Abstract:

The present invention relates to an If blocker or a pharmaceutically acceptable salt thereof for the treatment and/ or prevention of a feline patient suffering from heart failure (HF). The invention also relates to improving the quality of life, improving the general health condition as well as a prolonging the life expectancy in feline patients suffering from heart failure and/or heart failure due to one or more of the following etiologies HCM, DCM, RCM, UCM and /or ARVC.

Priority: EP20110177354 Applic. Date: 2011-08-12

Inventor: FOLGER MARTIN [DE]


Publication No.: WO2013024070A1  Published: 21/Feb/2013

Title: PHARMACEUTICAL AEROSOL PRODUCT FOR ADMINISTRATION BY ORAL OR NASAL INHALATION

Applicant/Assignee: NYCOMED GMBH

Application No.: WO2012EP65812 (PCT/EP2012/65812)   Filing Date: 13/Aug/2012

Abstract:

This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1, 1, 1, 2- tetrafluoroethane, or 1, 1, 1, 2, 3, 3, 3-heptafluoropropane.

Priority: US201161524803P Applic. Date: 2011-08-18; EP20110178042 Applic. Date: 2011-08-19

Inventor: MUELLER HELGERT [DE]; ENGELSTAETTER RENATE [DE]; BILDMANN ULRICH [DE]; BAUER ANDREA [US]; MCGLYNN PAUL [US]


Publication No.: WO2013024130A1  Published: 21/Feb/2013

Title: FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2012EP65989 (PCT/EP2012/65989)   Filing Date: 16/Aug/2012

Abstract:

The present invention relates to compounds defined by formula (I), wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this protein.

Priority: EP20110177808 Applic. Date: 2011-08-17

Inventor: TRIESELMANN THOMAS [DE]; HAMPRECHT DIETER [IT]; WAGNER HOLGER [DE]


Publication No.: WO2013024149A1  Published: 21/Feb/2013

Title: CRYSTALLINE FORMS OF OCTAHYDRO-3H-SPIRO [FURO [3, 4-C] QUINOLINE -1, 4 '-PYRAN] -9-OL

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2012EP66069 (PCT/EP2012/66069)   Filing Date: 17/Aug/2012

Abstract:

The present invention relates to crystalline forms of the compound of formula (I) as shown in the description and its hydrochloride or hydrobromide salts, to a process for the manufacture thereof, and to the use thereof in pharmaceutical compositions.

Priority: EP20110178029 Applic. Date: 2011-08-18

Inventor: OSTERMEIER MARKUS [DE]; GERLACH KAI [DE]; SIEGER PETER [DE]


Publication No.: WO2013024362A2  Published: 21/Feb/2013

Title: CARDIOVASCULAR THERAPEUTICS

Applicant/Assignee: OTAGO INNOVATION LIMITED

Application No.: WO2012IB02117 (PCT/IB2012/02117)   Filing Date: 17/Aug/2012

Abstract:

Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions.

Priority: US201161525140P Applic. Date: 2011-08-18

Inventor: PEMBERTON CHRISTOPHER JOSEPH [NZ]; RICHARDS ARTHUR MARK [NZ]; CHARLES CHRISTOPHER JOHN [NZ]; SIRIWARDENA MAITHRI [NZ]


Publication No.: WO2013024373A1  Published: 21/Feb/2013

Title: PHARMACEUTICAL COMPOSITION COMPRISING CEFUROXIME

Applicant/Assignee: DHANUKA LABORATORIES LTD

Application No.: WO2012IB53283 (PCT/IB2012/53283)   Filing Date: 28/Jun/2012

Abstract:

The present invention discloses a composition of taste masked oral suspension which comprises of bitter taste Cefuroxime axetil, having integral coating of lipid and sweetener system. The sweetener system which is used in composition is disclosed in the invention. The said composition delivers substantial amount of drug immediately at the gastric p H with improved palatability.

Priority: IN2011DE02275 Applic. Date: 2011-08-12

Inventor: DHANUKA MANISH [IN]; DHOKA VISHAL ASHOKA [IN]; SRIVASTAVA RAVI PRATAP [IN]; DHOKA ASHOKA [IN]


Publication No.: WO2013024376A1  Published: 21/Feb/2013

Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROTHROMBOSIS

Applicant/Assignee:

Application No.: WO2012IB53673 (PCT/IB2012/53673)   Filing Date: 19/Jul/2012

Abstract:

The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration- transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may foe used to treatment of vascular disorders or conditions such as thrombotic cerebrovascular or cardiovascular disease or its associated complications.

Priority: US201161523860P Applic. Date: 2011-08-16

Inventor: KANDULA MAHESH [IN]


Publication No.: WO2013024425A1  Published: 21/Feb/2013

Title: COMBINATIONS OF CORROLES AND STATINS

Applicant/Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD

Application No.: WO2012IB54124 (PCT/IB2012/54124)   Filing Date: 14/Aug/2012

Abstract:

Embodiments of the invention relate to methods of treatment a cardiovascular disease in a patient comprising administering an effective amount of a statin or a pharmaceutically acceptable salt thereof in combination with an effective amount of a transition metal complex of a corrole, an optically active isomer thereof or a pharmaceutically acceptable salt thereof. Further embodiments refer to pharmaceutical compositions comprising a statin and a corrole.

Priority: US201161523476P Applic. Date: 2011-08-15

Inventor: GROSS ZEEV [IL]; AVIRAM MICHAEL [IL]; HABER ADI [IL]


Publication No.: WO2013024487A1  Published: 21/Feb/2013

Title: ANTI- VITILIGO COMPOSITION

Applicant/Assignee: SALAFIA ELIZABETH

Application No.: WO2012IN00110 (PCT/IN2012/00110)   Filing Date: 17/Feb/2012

Abstract:

The invention deals with a novel composition for the treatment of vitiligo comprising of: : Benzyl peroxide, Precipitate Sulphur, Clobatesol dipropionate and Trioxaralen.. The ingredients and the concentrations of the ingredients of composition are selected in way to provide superior efficacy and safety even on prolonged use as well as to care of serious adverse effects like atrophy observed with the use of potent steroids.

Priority: IN2011MU02303 Applic. Date: 2011-08-16

Inventor: SALAFIA ANTONIO


Publication No.: WO2013024898A1  Published: 21/Feb/2013

Title: HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG

Applicant/Assignee: NIPPON SHINYAKU CO., LTD

Application No.: WO2012JP70902 (PCT/JP2012/70902)   Filing Date: 17/Aug/2012

Abstract:

The primary purpose of the present invention is to provide a novel heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the present invention can include a heterocyclic compound represented by general formula (1), a tautomer thereof, or a pharmaceutically acceptable salt thereof. (In the formula, R1 and R2 are identical or different and represent an aromatic ring or the like, and the ring (A) represents a heterocycle.) This compound or pharmaceutically acceptable salt thereof has high mPGES-1 inhibitory activity and can be used as a prophylactic agent or therapeutic agent for diseases involving mPGES-1, e.g., rheumatoid arthritis, osteoarthritis, temporomandibular joint disease, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignancy, or neurodegenerative disease.

Priority: JP20110179134 Applic. Date: 2011-08-18

Inventor: OTSU HIRONORI [JP]


Publication No.: WO2013025479A1  Published: 21/Feb/2013

Title: JAML SPECIFIC BINDING AGENTS, ANTIBODIES, AND USES RELATED THERETO

Applicant/Assignee: EMORY UNIVERSITY

Application No.: WO2012US50286 (PCT/US2012/50286)   Filing Date: 10/Aug/2012

Abstract:

Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.

Priority: US201161523886P Applic. Date: 2011-08-16; US201161563064P Applic. Date: 2011-11-23

Inventor: PARKOS CHARLES A [US]; WEBER DOMINIQUE A [US]


Publication No.: WO2013025696A1  Published: 21/Feb/2013

Title: OPHTHALMIC FORMULATIONS AND PROCESSES FOR THEIR PREPARATION

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD, TEVA PHARMACEUTICALS USA, INC

Application No.: WO2012US50758 (PCT/US2012/50758)   Filing Date: 14/Aug/2012

Abstract:

The invention relates to a process for preparing ophthalmic formulations and to formulations containing a suspension of an ophthalmic drug in an aqueous vehicle. The invention further relates to the production of stable ophthalmic formulations that have a minimal propensity to form drug aggregates.

Priority: US201161523467P Applic. Date: 2011-08-15; US201261588444P Applic. Date: 2012-01-19

Inventor: CETINA-CIZMEK BISERKA [HR]; BRACKO DANKA [HR]; MIOCIC SANDRA [HR]; TUNJIC IVA [HR]


Publication No.: WO2013025733A1  Published: 21/Feb/2013

Title: LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Applicant/Assignee: INTERMUNE, INC

Application No.: WO2012US50824 (PCT/US2012/50824)   Filing Date: 14/Aug/2012

Abstract:

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Priority: US201161570739P Applic. Date: 2011-12-14; US201261613395P Applic. Date: 2012-03-20; US201261674214P Applic. Date: 2012-07-20; US201161523776P Applic. Date: 2011-08-15

Inventor: BUCKMAN BRAD O [US]; NICHOLAS JOHN B [US]; EMAYAN KUMARASWAMY [US]; SEIWERT SCOTT D [US]


Publication No.: WO2013025870A2  Published: 21/Feb/2013

Title: EFFECTIVE DEPILATORY ARTICLE

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: WO2012US51073 (PCT/US2012/51073)   Filing Date: 16/Aug/2012

Abstract:

An aqueous depilatory composition comprising a thioglycolate salt and a fluoride ion source.

Priority: US201161524360P Applic. Date: 2011-08-17

Inventor: SMITH PAUL JAMES [GB]; WATTS GRAEME WILLIAM [GB]; ROWE CORALIE CLAUDE MONIQUE [GB]; CAMPBELL SARAH JAYNE [GB]; DRING NEIL CHARLES [GB]; SAGEL PAUL ALBERT [US]; PASSI RAJEEV KUMAR [US]; MITRA SHEKHAR [US]; BROYLES NORMAN SCOTT [US]


Publication No.: WO2013025872A1  Published: 21/Feb/2013

Title: DEPILATORY ARTICLE WITH SUBSTRATE

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: WO2012US51077 (PCT/US2012/51077)   Filing Date: 16/Aug/2012

Abstract:

A depilatory article comprising a substrate and a depilatory composition disposed on said substrate forming a coated region of the substrate, wherein at least a portion of the surface of the coated region of the substrate has an average surface free energy measured by the method herein of at least 30 mJ/m2, preferably from 31 mJ/m2 to 72 mJ/m2, more preferably from 32 mJ/m2 to 55 mJ/m2, even more preferably from 33 mJ/m2 to 46 mJ/m2 and even more preferably still from 34 mJ/m2 to 38 mJ/m2.

Priority: US201161524367P Applic. Date: 2011-08-17

Inventor: SMITH PAUL JAMES [GB]; SAGEL PAUL ALBERT [US]; PASSI RAJEEV KUMAR [US]; MITRA SHEKHAR [US]; BROYLES NORMAN SCOTT [US]


Publication No.: WO2013025893A1  Published: 21/Feb/2013

Title: PERSONAL CARE COMPOSITIONS COMPRISING AN ANTI-IRRITATION AGENT

Applicant/Assignee: THE GILLETTE COMPANY

Application No.: WO2012US51119 (PCT/US2012/51119)   Filing Date: 16/Aug/2012

Abstract:

A personal care composition comprising an anti-irritation agent such as a zinc pyrithione, a zinc salt or a combination thereof.

Priority: US201161524060P Applic. Date: 2011-08-16

Inventor: COFFINDAFFER TIMOTHY WOODROW [US]; HEATH BENJAMIN PARKER [US]; KEMP HELEN ROCHELLE [US]; WILLICUT ROBERT JOHN [US]; SCHWARTZ JAMES ROBERT [US]


Publication No.: WO2013025940A1  Published: 21/Feb/2013

Title: ANGIOGENESIS PROMOTED BY ALPHA-KERATOSE

Applicant/Assignee: KERANETICS LLC

Application No.: WO2012US51212 (PCT/US2012/51212)   Filing Date: 16/Aug/2012

Abstract:

Described herein are compositions comprising alpha keratose and the ability of such compositions to promote vascularization and angiogenesis around a wound site, and methods for the use of such compositions alone or in combination with other keratin sub-fractions and non-keratin tissue scaffolds to modulate angiogenesis.

Priority: US201161524593P Applic. Date: 2011-08-17

Inventor: BURNETT LUKE [US]; JOHNSON CHAD [US]


Publication No.: WO2013025984A2  Published: 21/Feb/2013

Title: CANNABINOID RECEPTOR TREATMENTS

Applicant/Assignee: TEMPLE UNIVERSITY

Application No.: WO2012US51330 (PCT/US2012/51330)   Filing Date: 17/Aug/2012

Abstract:

The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.

Priority: US201161524883P Applic. Date: 2011-08-18

Inventor: EISENSTEIN TOBY K [US]; HARTZELL REBECCA R [US]; ADLER MARTIN W [US]; MEISSIER JOSEPH J [US]


Publication No.: WO2013026264A1  Published: 28/Feb/2013

Title: CB1 ACCEPTOR INHIBITOR COMPOUND WITH NITROGEN-CONTAINING AROMATIC RING HAVING HYDROXYL AND USE THEREOF

Applicant/Assignee:

Application No.: WO2012CN01119 (PCT/CN2012/01119)   Filing Date: 22/Aug/2012

Abstract:

Disclosed is a cannabinoid (CB1) acceptor inhibitor compound with nitrogen-containing aromatic ring having hydroxyl shown as general formula I and a physiologically acceptable salt and solvate thereof. Wherein each substituent definition is as described in the description. The compound can be used to prepare medicines for drug rehabilitation, losing weight and treating diabetes, etc.

Priority: CN20111242456 Applic. Date: 2011-08-23

Inventor: FAN RULIN [CN]; YAO HU [CN]; FENG JIANKE [CN]; QIAO LIN [CN]; YUAN CHEN [CN]


Publication No.: WO2013026487A1  Published: 28/Feb/2013

Title: RIGID MOULDED BODY FOR TREATING PRURITUS

Applicant/Assignee:

Application No.: WO2011EP64635 (PCT/EP2011/64635)   Filing Date: 25/Aug/2011

Abstract:

The invention relates to a rigid moulded body which comprises, essentially, a plurality of sand grains which are provided with a wax covering and which adhere to each other, for removing or abating pruritus. In one embodiment of the invention, the wax is essentially made of bees wax.

Priority: WO2011EP64635 Applic. Date: 2011-08-25

Inventor: BEERMANN NORBERT [DE]


Publication No.: WO2013026553A1  Published: 28/Feb/2013

Title: COMPOSITION COMPRISING EDOXABAN

Applicant/Assignee: RATIOPHARM GMBH

Application No.: WO2012EP03512 (PCT/EP2012/03512)   Filing Date: 17/Aug/2012

Abstract:

The invention relates to compositions and dosage forms containing edoxaban and a C02-forming agent, preferably for immediate release. Further the invention relates to the method for preparing said dosage forms and their use in the treatment of thrombotic diseases.

Priority: EP20110006839 Applic. Date: 2011-08-22; US201161526065P Applic. Date: 2011-08-22

Inventor: STEFAN RALPH [DE]; MEERGANS DOMINIQUE [DE]


Publication No.: WO2013026772A1  Published: 28/Feb/2013

Title: FLURBIPROFEN AND RELATED COMPOUNDS FOR THE TREATMENT OF SKIN DISEASES

Applicant/Assignee: JOHANN WOLFGANG GOETHE-UNIVERSITAET

Application No.: WO2012EP66034 (PCT/EP2012/66034)   Filing Date: 16/Aug/2012

Abstract:

The present invention relates to the use of a compound according to the following formula (I), wherein R1 or R2 is a group selected from H, -CH3, -CH2CH3, -CH2CH2CH3, and - CH2CH2CH2CH3 or can be taken together with another to give a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring, or a cyclohexyl ring, R3 is a group selected from -COOH, - COOR6, -CONH2, -CONHR6, -CONR6R7, -CONHSO2R6, -COO-(CH2)3-CH2OH, -COO- (CH2)4-ONO2, -COO-PhOCH3-C2H2-COO-(CH2)4-ONO2, tetrazolyl, and a -COOH bioisostere, R4 or R5 is a group selected from -Cl, -F, -Br, -I, -CF3, -OCF3, -SCF3, -OCH3, - OCH2CH3, -CN, -CH=CH2, -CH2OH, and -NO2, R6 ot R7 is a group selected from -CH3, - CH2CH3, -CH2CH2CH3, and -CH2CH2CH2CH3, and m or n is an integer selected from 0, 1, 2, and 3, or a nitro-variant of said compound, and pharmaceutically acceptable salts of said compound, preferably an (R)-enantiomer thereof, such as Tarenflurbil ((R)-Flurbiprofen), for use in the treatment of skin diseases, preferably for the treatment of dermatitis.

Priority: GB20110014289 Applic. Date: 2011-08-19

Inventor: TEGEDER IRMGARD [DE]; GEISSLINGER GERD [DE]; LOETSCH JOERN [DE]


Publication No.: WO2013026878A1  Published: 28/Feb/2013

Title: ANTI-VCAM-1 NANOBODIES

Applicant/Assignee: UNIVERSITE JOSEPH FOURIER

Application No.: WO2012EP66348 (PCT/EP2012/66348)   Filing Date: 22/Aug/2012

Abstract:

The present invention relates to nanobodies specifically directed against VCAM-1 and to the use thereof in medical imaging and in diagnostic, prognostic and treatment methods.

Priority: FR20110057478 Applic. Date: 2011-08-23

Inventor: GHEZZI CATHERINE [FR]; FAGRET DANIEL [FR]; BROISAT ALEXIS [FR]; DEVOOGDT NICK [BE]; LAHOUTTE TONY [BE]; MUYDERMANS SERGE [BE]


Publication No.: WO2013027065A1  Published: 28/Feb/2013

Title: OPHTHALMIC FORMULATIONS

Applicant/Assignee: ALTACOR LIMITED

Application No.: WO2012GB52082 (PCT/GB2012/52082)   Filing Date: 24/Aug/2012

Abstract:

There is provided inter alia a germicidal aqueous formulation, suitable for use in the eye, which has a pH of from 4.0 to 6.5 and which comprises 4.0 to 7.5% w/w of povidone-iodine and a viscosity increasing agent, the formulation buffered with a buffer concentration of 25 mM to 75 mM.

Priority: GB20110014725 Applic. Date: 2011-08-25

Inventor: CRAWFORD FRANCESCA [GB]; GUNNING PHILIP [GB]


Publication No.: WO2013028140A1  Published: 28/Feb/2013

Title: TRIBULUS TERRESTRIS, AVENA SATIVA AND PANAX GINSENG EXTRACT COMBINATION

Applicant/Assignee:

Application No.: WO2012TR00044 (PCT/TR2012/00044)   Filing Date: 05/Mar/2012

Abstract:

The present invention, is related to a herbal pharmaceutical product, obtained from the defined parts of the tribulus terrestris, avena sativa and panax ginseng plants, in order to be used as a supplement and support to increase muscle strength, body stamina and physical performance and in order to treat cardiovascular diseases and the present invention is also related to the formulation of said product.

Priority: TR20110008485 Applic. Date: 2011-08-23

Inventor: ERASLAN MUSTAFA [TR]; TEKIN MUSTAFA [TR]


Publication No.: WO2013028177A1  Published: 28/Feb/2013

Title: FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF

Applicant/Assignee: KYTHERA BIOPHARMACEUTICALS, INC

Application No.: WO2011US48806 (PCT/US2011/48806)   Filing Date: 23/Aug/2011

Abstract:

The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Priority: WO2011US48806 Applic. Date: 2011-08-23

Inventor: HODGE ROBERT EMIL [US]; WEBSTER JEFFREY DOUGLAS [US]; MORIARTY ROBERT M [US]


Publication No.: WO2013028852A1  Published: 28/Feb/2013

Title: SYSTEMS, DEVICES, METHODS, AND ADMIXTURES OF TRANSPONDERS AND FOOD PRODUCTS FOR INDICATION OF FOOD ATTRIBUTES

Applicant/Assignee: ELWHA LLC

Application No.: WO2012US52048 (PCT/US2012/52048)   Filing Date: 23/Aug/2012

Abstract:

Systems, devices, admixtures, and methods are described including transponder devices (e.g., a palatable transponder, an edible transponder, a palatable radio frequency identification (RFID) tag, an edible RFID tag, etc.) for admixing with a food product.

Priority: US201113199360 Applic. Date: 2011-08-25; US201113199371 Applic. Date: 2011-08-25; US201113199358 Applic. Date: 2011-08-25; US201113199359 Applic. Date: 2011-08-25; US201113199372 Applic. Date: 2011-08-25; US201113199370 Applic. Date: 2011-08-25

Inventor: AIDEN EREZ LIEBERMAN [US]; BAYM MICHAEL H [US]; HOLMAN PAUL [US]; HYDE RODERICK A [US]; JUNG EDWARD K Y [US]; KARE JORDIN T [US]; MYHRVOLD NATHAN P [US]; WOOD JR LOWELL L [US]


Publication No.: WO2013028968A1  Published: 28/Feb/2013

Title: 3-DIMENSIONAL CARDIAC FIBROBLAST DERIVED EXTRACELLULAR MATRIX

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: WO2012US52252 (PCT/US2012/52252)   Filing Date: 24/Aug/2012

Abstract:

A bioscaffold made from an isolated cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) is disclosed. The bioscaffold can be used as an epicardial patch for die delivery of therapeutic cells into myocardial tissue. Methods of making the 3-dimensional extracellular matrix using cultured cardiac fibroblasts are also disclosed.

Priority: US201161575658P Applic. Date: 2011-08-25

Inventor: SCHMUCK ERIC [US]; SAUPE KURT [US]


Publication No.: WO2013029194A1  Published: 07/Mar/2013

Title: USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MELOXICAM AND PIROXICAM, ADMINISTERED INTRAVAGINALLY, FOR INTERRUPTION OF A WOMAN'S OVULATION PROCESS

Applicant/Assignee: UNIVERSIDAD DE SANTIAGO DE CHILE

Application No.: WO2011CL00049 (PCT/CL2011/00049)   Filing Date: 26/Aug/2011

Abstract:

The invention relates to the use of the non-steroidal anti-inflammatory compounds meloxicam and piroxicam as an intravaginal topical preparation for interrupting a woman's ovulation process.

Priority: WO2011CL00049 Applic. Date: 2011-08-26

Inventor: CARDENAS SANKAN HUGO [CL]; CROXATTO AVONI HORACIO [CL]; RABAGLIATI CANESSA FRANCO [CL]; ZAPATA RAMIREZ PAULA [CL]; GALVEZ PEREZ PAULA [CL]; ALTBIR DRULLINSKY DORA [CL]; VELASQUEZ CUMPLIDO LUIS [CL]


Publication No.: WO2013029198A1  Published: 07/Mar/2013

Title: ADEFOVIR DIPIVOXIL SOLID FORMULATION AND PREPARATION METHOD THEREFOR

Applicant/Assignee: TIANJIN TAIPU PHARMACEUTICAL SCIENCE & TECHNOLOGYDEVELOPMENT CO., LTD

Application No.: WO2011CN01440 (PCT/CN2011/01440)   Filing Date: 29/Aug/2011

Abstract:

An Adefovir Dipivoxil solid formulation and preparation method therefor. The method includes heating a pharmaceutical solvent and an inclusion agent for dissolution, leaving it for cooling to the room temperature, then mixing with Adefovir Dipivoxil, and suctioning the solvent to give Adefovir Dipivoxil granules, and further mixing with a pharmaceutical additive for uniform tableting or capsulation, wherein the Adefovir Dipivoxil granules are 0.5-3 parts, the pharmaceutical additive is 1-25 parts, and the Adefovir Dipivoxil granules comprise Adefovir Dipivoxil of 0.5-1 parts and the inclusion agent of 0.05-0.15 parts.

Priority: WO2011CN01440 Applic. Date: 2011-08-29

Inventor: ZHOU SHIWANG [CN]; ZHU JIANQIANG [CN]; TIAN QINGSONG [CN]


Publication No.: WO2013029297A1  Published: 07/Mar/2013

Title: USE OF PATCHOULI ALCOHOL IN PREPARATION OF DRUG AGAINST HELICOBACTER PYLORI

Applicant/Assignee: DONGGUAN MATHEMATICAL ENGINEERING ACADEMY OF CHINESE MEDICINE, GUANGZHOU UNIVERSITY OF CHINESE MEDIC

Application No.: WO2011CN81153 (PCT/CN2011/81153)   Filing Date: 22/Oct/2011

Abstract:

The present invention relates to a use of patchouli alcohol in the preparation of a drug against Helicobacter pylori. The drug according to the present invention is composed of the patchouli alcohol and pharmaceutically acceptable additives, wherein the content of the patchouli alcohol is 0.5-70%. The patchouli alcohol according to the present invention has a quite narrow antimicrobial spectrum, and may selectively inhibit Helicobacter pylori without influencing growth and propagation of other bacterial populations (including other gram negative bacteria). The patchouli alcohol may kill Helicobacter pylori without damaging probiotics, and may keep an ecological balance of bacterial populations in the intestinal tract of human body. Therefore, the patchouli alcohol may be used for treatment of diseases caused by infection of Helicobacter pylori, such as gastritis, peptic ulcer and early gastric cancer.

Priority: CN20111249038 Applic. Date: 2011-08-26

Inventor: LAI XIAOPING [CN]; SU ZIREN [CN]; CHEN JIANNAN [CN]; LI YUCUI [CN]; HE JINGJIN [CN]


Publication No.: WO2013029525A1  Published: 07/Mar/2013

Title: PHARMACEUTICAL COMPOSITION COMPRISING IODINE POLYMER AND GLUCOCORTICOSTEROID FOR TREATING DERMATITIS

Applicant/Assignee: JIANGSU DEDA PHARMACEUTICALS CO. LIMITED

Application No.: WO2012CN80656 (PCT/CN2012/80656)   Filing Date: 28/Aug/2012

Abstract:

A pharmaceutical composition for treating dermatitis consists of 0.01% - 5% of povidone-iodine, 0.01% - 0% of glucocorticosteroid, 0.001% - 0.5% of potassium iodate and the rest of pharmaceutical acceptable carriers, wherein the glucocorticosteroid is propionate or halometasone.

Priority: CN20111251419 Applic. Date: 2011-08-29

Inventor: LIANG BO [CN]; GUO JING [CN]; LU YONG [CN]


Publication No.: WO2013030218A1  Published: 07/Mar/2013

Title: SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7

Applicant/Assignee: HYBRIGENICS SA

Application No.: WO2012EP66741 (PCT/EP2012/66741)   Filing Date: 29/Aug/2012

Abstract:

The present invention relates to quinazolin-4-one compounds of formula (I'), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.

Priority: EP20110306096 Applic. Date: 2011-09-02

Inventor: COLLAND FREDERIC [FR]; GOURDEL MARIE-EDITH [FR]


Publication No.: WO2013030288A1  Published: 07/Mar/2013

Title: SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF

Applicant/Assignee: BAYER INTELLECTUAL PROPERTY GMBH, BAYER PHARMA AKTIENGESELLSCHAFT

Application No.: WO2012EP66876 (PCT/EP2012/66876)   Filing Date: 30/Aug/2012

Abstract:

The present application relates to new substituted annellated pyrimidines, a method for the production thereof, the use thereof in isolation or in combination for the treatment and/or prophylaxis of diseases, and the use thereof to produce medicines for the treatment and/or prophylaxis of diseases, more particularly for the treatment and/or prophylaxis of cardiovascular diseases.

Priority: DE20111082041 Applic. Date: 2011-09-02; DE201210200351 Applic. Date: 2012-01-11

Inventor: FOLLMANN MARKUS [DE]; STASCH JOHANNES-PETER [DE]; REDLICH GORDEN [DE]; GRIEBENOW NILS [DE]; LANG DIETER [DE]; WUNDER FRANK [DE]; HUEBSCH WALTER [DE]; LINDNER NIELS [DE]; VAKALOPOULOS ALEXANDROS [DE]; TERSTEEGEN ADRIAN [DE]


Publication No.: WO2013030365A1  Published: 07/Mar/2013

Title: NOVEL ROCK KINASE INHIBITORS

Applicant/Assignee: AMAKEM NV

Application No.: WO2012EP67016 (PCT/EP2012/67016)   Filing Date: 31/Aug/2012

Abstract:

The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and respiratory diseases.

Priority: EP20110179491 Applic. Date: 2011-08-31

Inventor: ALEN JO [BE]; BOLAND SANDRO [BE]; BOURIN ARNAUD PIERRE JEAN [BE]; DEFERT OLIVIER [FR]; LEYSEN DIRK [BE]


Publication No.: WO2013030366A1  Published: 07/Mar/2013

Title: NOVEL SOFT ROCK INHIBITORS

Applicant/Assignee: AMAKEM NV

Application No.: WO2012EP67017 (PCT/EP2012/67017)   Filing Date: 31/Aug/2012

Abstract:

The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases and ophthalmic diseases.

Priority: EP20110179491 Applic. Date: 2011-08-31

Inventor: ALEN JO [BE]; BOLAND SANDRO [BE]; BOURIN ARNAUD PIERRE JEAN [BE]; DEFERT OLIVIER [FR]; LEYSEN DIRK [BE]


Publication No.: WO2013030367A1  Published: 07/Mar/2013

Title: BIPHENYLCARBOXAMIDES AS ROCK KINASE INHIBITORS

Applicant/Assignee: AMAKEM NV

Application No.: WO2012EP67018 (PCT/EP2012/67018)   Filing Date: 31/Aug/2012

Abstract:

The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases, gastrointestinal diseases and respiratory diseases.

Priority: EP20110179491 Applic. Date: 2011-08-31

Inventor: ALEN JO [BE]; BOLAND SANDRO [BE]; BOURIN ARNAUD PIERRE JEAN [BE]; DEFERT OLIVIER [FR]; LEYSEN DIRK [BE]


Publication No.: WO2013030679A2  Published: 07/Mar/2013

Title: SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION

Applicant/Assignee: QLT INC

Application No.: WO2012IB02210 (PCT/IB2012/02210)   Filing Date: 29/Aug/2012

Abstract:

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Priority: US201161528736P Applic. Date: 2011-08-29; US201261644397P Applic. Date: 2012-05-08

Inventor: CADDEN SUZANNE [CA]; HAO YONG [CA]; UTKHEDE DEEPANK [CA]; RUBINCHIK VALERY [CA]; KJELLBOTN CHARLES RICHARD [CA]


Publication No.: WO2013030725A1  Published: 07/Mar/2013

Title: METHODS FOR TREATING CARDIOVASCULAR DISORDERS

Applicant/Assignee: WOCKHARDT LIMITED

Application No.: WO2012IB54257 (PCT/IB2012/54257)   Filing Date: 23/Aug/2012

Abstract:

There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.

Priority: IN2011MU02395 Applic. Date: 2011-08-26; IN2011MU02399 Applic. Date: 2011-08-26; IN2011MU02411 Applic. Date: 2011-08-27

Inventor: KODGULE MANDAR MADHUKAR [IN]; NAKHAT PREMCHAND DALICHANDJI [IN]; GUPTA AMIT [IN]; JAIN GIRISH KUMAR [IN]


Publication No.: WO2013031729A1  Published: 07/Mar/2013

Title: PROPHYLACTIC/THERAPEUTIC AGENT FOR CARDIOVASCULAR COMPLICATIONS OF DIABETES

Applicant/Assignee: OSAKA UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE

Application No.: WO2012JP71594 (PCT/JP2012/71594)   Filing Date: 27/Aug/2012

Abstract:

The purpose of the present invention is to provide a drug having excellent prophylactic or therapeutic effect against cardiovascular complications of diabetes, the drug containing a compound for inhibiting neutral fat accumulation in cardiovascular tissue or cells. The present invention pertains to a prophylactic/therapeutic drug for cardiovascular complications of diabetes, the drug containing a compound for inhibiting neutral fat accumulation (preferably, medium-chain fatty acid and/or medium-chain triglyceride).

Priority: JP20110184318 Applic. Date: 2011-08-26

Inventor: HIRANO KEN-ICHI [JP]; YASUI YOKO [JP]; IKEDA YOSHIHIKO [JP]; SETOU MITSUTOSHI [JP]; ZAIMA NOBUHIRO [JP]


Publication No.: WO2013031930A1  Published: 07/Mar/2013

Title: IMINE DERIVATIVE

Applicant/Assignee: AJINOMOTO CO., INC

Application No.: WO2012JP72103 (PCT/JP2012/72103)   Filing Date: 31/Aug/2012

Abstract:

Provided is a novel imine derivative having an inhibitory activity on activated blood coagulation factor X or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by formula (I) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof.

Priority: JP20110189722 Applic. Date: 2011-08-31

Inventor: MATSUMOTO KAYO [JP]; NAKAGAWA TADAKIYO [JP]; MIYANAGA WATARU [JP]; MURONOI SHIN [JP]; SUGIKI MASAYUKI [JP]; YAMADA TATSUHIRO [JP]; NOGUCHI MISATO [JP]; SHIMA YOICHIRO [JP]; TANIGUCHI SHINYA [JP]; TAKADA ATSUSHI [JP]


Publication No.: WO2013031932A1  Published: 07/Mar/2013

Title: P-MENTHANE-3,8-DIOL ISOMER MIXTURE, COLD-SENSITIVE COMPOSITION CONTAINING SAME, AND PRODUCT CONTAINING SAID COLD-SENSITIVE COMPOSITION

Applicant/Assignee: TAKASAGO INTERNATIONAL CORPORATION

Application No.: WO2012JP72108 (PCT/JP2012/72108)   Filing Date: 31/Aug/2012

Abstract:

The present invention pertains to a p-menthane-3,8-diol isomer mixture composed of 50 mass% or more of (1S) forms, and a cold-sensitive composition containing same. The present invention also pertains to a perfume composition, a food and beverage product, a cosmetic, a daily sundry, an oral composition, and a pharmaceutical product containing 0.0001-90 mass% of the p-menthane-3,8-diol isomer mixture.

Priority: JP20110189515 Applic. Date: 2011-08-31

Inventor: KOMATSUKI YASUHIRO [JP]; TANAKA SHIGERU [JP]; ISHIDA KENYA [JP]


Publication No.: WO2013032184A2  Published: 07/Mar/2013

Title: COMPOSITION COMPRISING PYRAZINO-TRIAZINE DERIVATIVES

Applicant/Assignee: JW PHARMACEUTICAL CORPORATION

Application No.: WO2012KR06774 (PCT/KR2012/06774)   Filing Date: 24/Aug/2012

Abstract:

Provided in the present invention is a composition comprising: pyrazino-triazine derivatives

and pharmaceutically acceptable salts thereof. The composition comprises: a solubilizing agent

or a stabilizer, and has significantly superior solubility and stability.

Priority: KR20110085493 Applic. Date: 2011-08-26; US201161555427P Applic. Date: 2011-11-03

Inventor: CHOI MIN-SEOK [KR]; KIM YOUNG-HOON [KR]


Publication No.: WO2013032230A2  Published: 07/Mar/2013

Title: PHARMACEUTICAL ANGIOGENIC COMPOSITION INCLUDING A MICRORNA-382 ACTIVATOR

Applicant/Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Application No.: WO2012KR06909 (PCT/KR2012/06909)   Filing Date: 29/Aug/2012

Abstract:

The present invention relates to an angiogenic composition, and more particularly, to a pharmaceutical angiogenic composition including a microRNA-382 activator. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis. Therefore, provided in the present invention is the pharmaceutical angiogenic composition which includes the microRNA-382 activator, which is angiogenic and thus promotes cell proliferation, and can be valuably used in treating injuries, ischemic myocardial infarctions, or foot ischemia.

Priority: KR20110086986 Applic. Date: 2011-08-30; KR20120094792 Applic. Date: 2012-08-29

Inventor: LEE YOU MIE [KR]


Publication No.: WO2013032231A2  Published: 07/Mar/2013

Title: PHARMACEUTICAL ANTI-ANGIOGENIC COMPOSITION INCLUDING A MICRORNA-382 INHIBITOR

Applicant/Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Application No.: WO2012KR06910 (PCT/KR2012/06910)   Filing Date: 29/Aug/2012

Abstract:

The present invention relates to an anti-angiogenic composition, and more particularly, to a pharmaceutical anti-angiogenic composition including a microRNA-382 inhibitor. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis induced in a low oxygen environment. Therefore, the pharmaceutical composition of the present invention inhibits microRNA-382 and thus inhibits angiogenesis and cell proliferation, and is expected ultimately to be valuably used in the treatment of cancer.

Priority: KR20110086987 Applic. Date: 2011-08-30; KR20120094794 Applic. Date: 2012-08-29

Inventor: LEE YOU MIE [KR]


Publication No.: WO2013032333A1  Published: 07/Mar/2013

Title: ORAL DOSAGE UNITS CONTAINING ASTAXANTHIN, PHOSPHOLIPIDS AND OMEGA-3 FATTY ACIDS

Applicant/Assignee: ALGAE BIOTECH S.L

Application No.: WO2012NL50599 (PCT/NL2012/50599)   Filing Date: 31/Aug/2012

Abstract:

The invention relates to a method of preparing an oral dosage unit containing 200-1200 mg of a micronutrient composition, said micronutrient composition comprising: 0.1-5 mg of astaxanthin

DEG 50-500 mg of ?3-fatty acids selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and combinations thereof

DEG 1-300 mg of glycerophospholipids

and DEG 0-600 mg of other components

said method comprising mixing together: DEG 0.5-20 parts by weight of microalgal astaxanthin isolate having an astaxanthin content of at least 1 wt.%

and DEG 80-99.5 parts by weight of one or more microalgal oil isolates, said one or more microalagal isolates containing at least 10 wt.% of co3-fatty acids selected from EPA, DHA and combinations thereof and/or at least 1 wt.% of glycerophospholipids. The invention also related to an oral dosage unit that is obtained by the aforementioned method. This oral dosage unit, when consumed on a daily basis over a prolonged period of time, offers the advantage that it prevents and reduces the risk of appearance of hypercholesterolemia, hyperlipidemia, cardiovascular conditions, immune conditions and cognitive decline.

Priority: EP20110179741 Applic. Date: 2011-09-01

Inventor: EVERS WILHELMUS CORNELIS JOHANNES MARIE [NL]


Publication No.: WO2013032784A1  Published: 07/Mar/2013

Title: NATRIURETIC POLYPEPTIDES

Applicant/Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Application No.: WO2012US51734 (PCT/US2012/51734)   Filing Date: 21/Aug/2012

Abstract:

This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.

Priority: US201161529113P Applic. Date: 2011-08-30; US201261648718P Applic. Date: 2012-05-18

Inventor: LEE CANDACE Y W [CA]; BURNETT JOHN C JR [US]


Publication No.: WO2013033176A1  Published: 07/Mar/2013

Title: DECITABINE DERIVATIVE FORMULATIONS

Applicant/Assignee: ASTEX PHARMACEUTICALS, INC

Application No.: WO2012US52816 (PCT/US2012/52816)   Filing Date: 29/Aug/2012

Abstract:

The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.

Priority: US201161529081P Applic. Date: 2011-08-30

Inventor: JOSHI-HANGAL RAJASHREE [US]; TANG CHUNLIN [US]; REDKAR SANJEEV [US]; RAVIVARAPU HARISH [US]


Publication No.: WO2013033194A1  Published: 07/Mar/2013

Title: LEVOTHYROXINE FORMULATIONS

Applicant/Assignee: FRESENIUS KABI USA, LLC

Application No.: WO2012US52838 (PCT/US2012/52838)   Filing Date: 29/Aug/2012

Abstract:

A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40: 1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10: 1.

Priority: US201161529084P Applic. Date: 2011-08-30

Inventor: JIANG Z [US]; USAYAPANT ARUNYA [US]; MONEN GEORGE [US]


Publication No.: WO2013033324A2  Published: 07/Mar/2013

Title: MATERIALS AND METHODS FOR MODULATING ACTIVITY OF BONE MARROW DERIVED CELLS

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC

Application No.: WO2012US53033 (PCT/US2012/53033)   Filing Date: 30/Aug/2012

Abstract:

Priority: US201161529662P Applic. Date: 2011-08-31

Inventor: CONRAD KIRK P [US]; SEGAL MARK S [US]


Publication No.: WO2013033563A1  Published: 07/Mar/2013

Title: PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA

Applicant/Assignee: NOVARTIS AG

Application No.: WO2012US53391 (PCT/US2012/53391)   Filing Date: 31/Aug/2012

Abstract:

Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3kDa but less than 11kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3kDa but less than 11kDa

and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

Priority: US201161529878P Applic. Date: 2011-08-31

Inventor: GEALL ANDREW [US]; VERMA AYUSH [US]


Publication No.: WO2013034040A1  Published: 14/Mar/2013

Title: CELECOXIB SOLID DISPERSION AND PREPARATION METHOD THEREFOR

Applicant/Assignee: JIANGSU HENGRUI MEDICINE CO., LTD

Application No.: WO2012CN79821 (PCT/CN2012/79821)   Filing Date: 08/Aug/2012

Abstract:

A celecoxib solid dispersion, comprising celecoxib and a carrier material selected from polyvinylpyrrolidone, copovidone and crospovidone, wherein a ratio by weight of the carrier material to celecoxib is as low as 0.2:1. The solid dispersion is prepared by co-dissolving the carrier material and celecoxib into an organic solvent, or dispersing the carrier material into an organic solvent having celecoxib and then removing the organic solvent. The solid dispersion may be used to prepare a variety of solid formulations.

Priority: CN20111278729 Applic. Date: 2011-09-08; CN2012103999 Applic. Date: 2012-01-09

Inventor: ZHAO DONG [CN]; ZUO JIAO [CN]; KANG LI [CN]; REN CHUNJUAN [CN]


Publication No.: WO2013034657A1  Published: 14/Mar/2013

Title: FRAGRANCE COMPOUNDS AND COMPOSITIONS

Applicant/Assignee: GIVAUDAN SA

Application No.: WO2012EP67449 (PCT/EP2012/67449)   Filing Date: 06/Sep/2012

Abstract:

Compounds of formula (I) wherein R is methyl or ethyl, having floral, green odor notes, their use as fragrance and perfumed products comprising them.

Priority: GB20110015409 Applic. Date: 2011-09-07

Inventor: GEIGER MARIUS [CH]; LOVCHIK MARTIN [CH]


Publication No.: WO2013034931A1  Published: 14/Mar/2013

Title: ORAL SUSPENSION

Applicant/Assignee: NOVA BIO-PHARMA TECHNOLOGIES LIMITED

Application No.: WO2012GB52216 (PCT/GB2012/52216)   Filing Date: 07/Sep/2012

Abstract:

A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical composition, and a method for the treatment of ALL in a human patient comprising administration of a therapeutically effective amount of the liquid pharmaceutical composition.

Priority: GB20110015569 Applic. Date: 2011-09-09

Inventor: WHITE PETER JOHN PITT [GB]


Publication No.: WO2013035072A1  Published: 14/Mar/2013

Title: BIOACTIVE NANOFIBRES

Applicant/Assignee:

Application No.: WO2012IB54626 (PCT/IB2012/54626)   Filing Date: 07/Sep/2012

Abstract:

The present invention relates to one or more nanofibres comprising an effective amount of one or more active agents, including one or more active agents being, or obtained, from a plant extract, and methods of using the nanofibres, including in delivery systems suitable for use in therapy or prevention of skin diseases or conditions.

Priority: US201161532437P Applic. Date: 2011-09-08

Inventor: VILE GLENN [NZ]; HOSIE IAIN CAMERON [NZ]; FEASEY SIMON VAUGHAN [NZ]


Publication No.: WO2013035113A1  Published: 14/Mar/2013

Title: COATED SUPPOSITORIES

Applicant/Assignee: LIPID PHARMACEUTICALS EHF

Application No.: WO2012IS50012 (PCT/IS2012/50012)   Filing Date: 06/Sep/2012

Abstract:

The invention relates to coating of suppositories containing free unsaturated fatty acid, fatty acid ethyl ester and fatty acid monoglyceride that are susceptible to oxidative degradation. The coating retards oxidative degradation of unsaturated fatty acids and gives the suppository a non-oily and smooth surface. The coating will enhance the shelf-life of the suppository and allow their storage at room temperature for extended time period. The coating may or may not contain medicament such as local anesthetic or steroid. According to this invention chemically unstable fatty acids in coated suppositories can be used to stimulate the process of defecation or to treat disorders such as hemorrhoids, bacterial infections, viral infections and inflammations, as well as against fissura ani and pruritus ani. Furthermore, coating suppositories,that contain high concentrations of free fatty acids,can reduce acid induced rectal irritation.

Priority: IS20110008980 Applic. Date: 2011-09-06

Inventor: LOFTSSON THORSTEINN [IS]


Publication No.: WO2013035757A1  Published: 14/Mar/2013

Title: PREPARATION COMPRISING HEXOSE-6-PHOSPHATE-MODIFIED CHOLESTEROL DERIVATIVE

Applicant/Assignee: KYOTO UNIVERSITY, GIFU UNIVERSITY

Application No.: WO2012JP72651 (PCT/JP2012/72651)   Filing Date: 05/Sep/2012

Abstract:

The present invention provides a compound represented by general formula (1). In general formula (1): G represents a hexose-6-phosphate group

and L represents a divalent linker group.

Priority: JP20110195229 Applic. Date: 2011-09-07

Inventor: UN KEITA [JP]; HASHIDA MITSURU [JP]; KAWAKAMI SHIGERU [JP]; KISO MAKOTO [JP]; UEKI AKIHARU [JP]; ANDO HIROMUNE [JP]


Publication No.: WO2013036115A1  Published: 14/Mar/2013

Title: PROCESS TO COAT AN ACTIVE AGENT TO A SURFACE

Applicant/Assignee: UNIVERSITEIT LEIDEN, UNIVERSITEIT TWENTE

Application No.: WO2012NL50616 (PCT/NL2012/50616)   Filing Date: 06/Sep/2012

Abstract:

The invention is directed to a process to prepare an object coated with an active agent by contacting an object, wherein the surface of the object has a pKa of between 4 and 7.4, with a buffered aqueous coating solution comprising a negatively charged active agent and wherein said buffered solution has a pH below the pKa, or by contacting an object, wherein the surface of the object has a pKa of between 7.4 and 10, with a buffered aqueous coating solution comprising a positively charged active agent and wherein said buffered solution has a pH above the pKa of the surface. The surface of the object may also be modified with organic molecules comprising ionisable groups which are bases and ionisable groups which are acids.

Priority: NL20112007382 Applic. Date: 2011-09-09

Inventor: VAN DER MAADEN KOEN [NL]; BOUWSTRA JOHANNA AALTJE [NL]; JISKOOT WIM [NL]; TAS NIELS ROELOF [NL]


Publication No.: WO2013036434A1  Published: 14/Mar/2013

Title: TETRAHYDRONAPHTHALENE DERIVATIVES AS T-TYPE CALCIUM CHANNEL BLOCKER

Applicant/Assignee: CONCERT PHARMACEUTICALS INC

Application No.: WO2012US53177 (PCT/US2012/53177)   Filing Date: 30/Aug/2012

Abstract:

This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: [Insert Formulas B, A, I, C, and E] as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.

Priority: US201113227047 Applic. Date: 2011-09-07

Inventor: TUNG ROGER [US]; MASSE CRAIG E [US]; PANDYA BHAUMIK A [US]


Publication No.: WO2013036568A1  Published: 14/Mar/2013

Title: HYALURONIC ACID/COLLAGEN- BASED DERMAL FILLER COMPOSITIONS AND METHODS FOR MAKING SAME

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US53853 (PCT/US2012/53853)   Filing Date: 06/Sep/2012

Abstract:

Hyaluronic acid and collagen may be crosslinked in aqueous solution as described herein. The crosslinked macromolecular matrices obtained in this process may be used as a hydrogel for implants and fillers for human aesthetic and therapeutic products.

Priority: US201161531533P Applic. Date: 2011-09-06

Inventor: POLLOCK JACOB F [US]; YU XIAOJIE [US]; MANESIS NICHOLAS J [US]


Publication No.: WO2013036596A2  Published: 14/Mar/2013

Title: SERPINF2-BINDING MOLECULES AND METHODS OF USE

Applicant/Assignee:

Application No.: WO2012US53900 (PCT/US2012/53900)   Filing Date: 06/Sep/2012

Abstract:

Priority: US201161531278P Applic. Date: 2011-09-06

Inventor: REED GUY L [US]


Publication No.: WO2013036610A2  Published: 14/Mar/2013

Title: COMPOSITIONS COMPRISING MG53 AND METHODS FOR THE TREATMENT AND PREVENTION OF AIRWAY INJURY

Applicant/Assignee: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Application No.: WO2012US53920 (PCT/US2012/53920)   Filing Date: 06/Sep/2012

Abstract:

Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof.

Priority: US201161531708P Applic. Date: 2011-09-07

Inventor: MA JIANJIE [US]; WEISLEDER NOAH [US]


Publication No.: WO2013036775A1  Published: 14/Mar/2013

Title: SILICONE COATED IMPLANTS

Applicant/Assignee: AXXIA PHARMACEUTICALS, LLC

Application No.: WO2012US54176 (PCT/US2012/54176)   Filing Date: 07/Sep/2012

Abstract:

Implants for delivery of therapeutic agents such as opioids, and the manufacture and uses of such implants are provided. In particular, subcutaneous drug delivery systems having a biocompatible thermoplastic elastomeric polymer matrix, a therapeutic agent embedded homogeneously in said matrix, and a biocompatible drug impermeable cross-linked silicone polymer coating said matrix and methods of making the same are provided.

Priority: US201161533131P Applic. Date: 2011-09-09

Inventor: HOLL RICHARD J [US]; HARTMAN KATHERINE [US]; GROSSMAN STUART A [US]; POLLOCK WAYNE C [US]


Publication No.: WO2013036835A1  Published: 14/Mar/2013

Title: NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Applicant/Assignee: SAGE THERAPEUTICS, INC

Application No.: WO2012US54261 (PCT/US2012/54261)   Filing Date: 07/Sep/2012

Abstract:

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

Priority: US201161532427P Applic. Date: 2011-09-08

Inventor: UPASANI RAVINDRA B [US]; HARRISON BOYD L [US]; ASKEW BENNY C JR [US]; DODART JEAN-COSME [US]; SALITURO FRANCESCO G [US]; ROBICHAUD ALBERT J [US]


Publication No.: WO2013037066A1  Published: 21/Mar/2013

Title: OCAB-BASED TOOLS FOR SCREENING OF THERAPEUTIC AGENTS, TREATING AND DIAGNOSING HEART DISEASE ASSOCIATED WITH CARDIAC REMODELING

Applicant/Assignee: UNIVERSITE LAVAL

Application No.: WO2012CA50638 (PCT/CA2012/50638)   Filing Date: 14/Sep/2012

Abstract:

It is shown herein that the expression of the OcaB protein is modulated, in cardiomyocytes, during cardiac remodeling (e.g., heart mypertrophy and/or fibrosis) and aging. The present application thus provides methods of characterizing an individual susceptibility to develop a heart disease associated with cardiac remodeling, methods of diagnosing a heart disease associated with cardiac remodeling in an individual, methods of characterizing the effectiveness of an agent in the treatment, prevention or alleviation of symptoms of heart disease associated with cardiac remodeling in an individual, screening methods to identify agents useful in the treatment, prevention or alleviation of symptoms of heart disease associated with cardiac remodeling based on the assessment of a parameter of an OcaB-based reagent.

Priority: US201161534520P Applic. Date: 2011-09-14

Inventor: PICARD FREDERIC [CA]; CARTER SOPHIE [CA]; COUET JACQUES [CA]


Publication No.: WO2013037390A1  Published: 21/Mar/2013

Title: 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS

Applicant/Assignee: SANOFI

Application No.: WO2011EP65719 (PCT/EP2011/65719)   Filing Date: 12/Sep/2011

Abstract:

The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Priority: WO2011EP65719 Applic. Date: 2011-09-12

Inventor: LOEHN MATTHIAS [DE]; MENDEZ-PEREZ MARIA [DE]; PFEIFFER-MAREK STEFANIA [DE]; KANNT AIMO [DE]; BEGIS GUILLAUME [FR]; JEANNOT FREDERIC [FR]; DUCLOS OLIVIER


Publication No.: WO2013037479A1  Published: 21/Mar/2013

Title: OPHTHTALMIC COMPOSITIONS COMPRISING PROSTAGLANDIN F2 ALPHA DERIVATIVES AND HYALURONIC ACID

Applicant/Assignee: VISIOTACT PHARMA

Application No.: WO2012EP03810 (PCT/EP2012/03810)   Filing Date: 11/Sep/2012

Abstract:

The present invention relates to a composition comprising at least one analogue of prostaglandin as active compound, and a stabilizing amount of at least one hyaluronic acid or a salt thereof, said composition being preservative-free

and to the use thereof for use in treating ocular hypertension and/or glaucoma in a subject in need thereof.

Priority: EP20110306137 Applic. Date: 2011-09-12

Inventor: HADJ-SLIMANE REDA [FR]


Publication No.: WO2013037566A1  Published: 21/Mar/2013

Title: AQUEOUS COMPOSITIONS COMPRISING ARBEKACIN

Applicant/Assignee: MEIJI SEIKA PHARMA CO., LTD, PARI PHARMA GMBH

Application No.: WO2012EP65265 (PCT/EP2012/65265)   Filing Date: 03/Aug/2012

Abstract:

The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory tract, wherein the composition is aerosolized and inhaled by the patient. Furthermore, the invention provides arbekacin hydrochloride.

Priority: EP20110180927 Applic. Date: 2011-09-12

Inventor: YAGI YUKIHIRO [JP]; TANAKA MASASHI [JP]; SUGANO TOSHIE [JP]; SHOJI KUNIKO [JP]; SANO NAO [JP]; KELLER MANFRED [DE]; HAHN MICHAEL [DE]; EGLE ROMAN [DE]


Publication No.: WO2013037624A1  Published: 21/Mar/2013

Title: PERFUMING ACETAL

Applicant/Assignee: FIRMENICH SA

Application No.: WO2012EP66533 (PCT/EP2012/66533)   Filing Date: 24/Aug/2012

Abstract:

The present invention concerns the use as perfuming ingredient of 4-dimethoxymethyl-1,3-dimethyl-1-cyclohexene in the form of any one of its stereoisomers or a mixture thereof, for instance to impart odor notes of the grapefruit and floral type.

Priority: EP20110180918 Applic. Date: 2011-09-12

Inventor: FANTINI PIERO [CH]


Publication No.: WO2013037650A1  Published: 21/Mar/2013

Title: COMPOSITIONS FOR ORAL ADMINISTRATION TO ANIMALS, PRODUCTION METHODS THEREOF AND USES OF SAME

Applicant/Assignee: FRIULCHEM SPA

Application No.: WO2012EP67005 (PCT/EP2012/67005)   Filing Date: 31/Aug/2012

Abstract:

The present invention relates to a solid appetising composition, the use thereof and the production method of same, said composition comprising in relation to the total weight thereof: 5 to 30 wt.-%, preferably 8 to 20 wt.-%, of at least one fat, selected from a liquid oil, a fatty substance, a wax or a mixture of same, wherein the liquid oil cannot constitute more than 8 wt.-% of the composition

0.001 to 85 wt.-% of at least one active substance

and 20 to 95 wt.-%, preferably 40 to 70 wt.-% of an appetising material, intended for use as a drug, nutraceutical or food supplement, for oral administration to mammals, not including humans, in particular for domestic animals such as dogs, cats and horses. Said solid composition is obtained by mixing the components, vaporising the fatty substances, size-grading the dry and fluid granular material, and compressing said granular material with a bouillon cube press.

Priority: WO2011EP65990 Applic. Date: 2011-09-15

Inventor: DERRIEU GUY [FR]; MAZZOLA GIANCARLO [CH]


Publication No.: WO2013037704A1  Published: 21/Mar/2013

Title: N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: WO2012EP67470 (PCT/EP2012/67470)   Filing Date: 07/Sep/2012

Abstract:

The present invention relates to compounds of the formula wherein R1 to R3 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

Priority: EP20110180930 Applic. Date: 2011-09-12

Inventor: GRETHER UWE [DE]; ROEVER STEPHAN [DE]


Publication No.: WO2013037708A1  Published: 21/Mar/2013

Title: A FAST DISSOLVING PHARMACEUTICAL COMPOSITION

Applicant/Assignee: FERRING B.V

Application No.: WO2012EP67507 (PCT/EP2012/67507)   Filing Date: 07/Sep/2012

Abstract:

The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises both the polysaccharides levan and inulin.

Priority: IN2011DE02683 Applic. Date: 2011-09-16

Inventor: AHUJA VARINDER [IN]; GUNDU BALACHENDAR [IN]; GUNJIKAR TEJAS [IN]


Publication No.: WO2013037721A1  Published: 21/Mar/2013

Title: 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: WO2012EP67615 (PCT/EP2012/67615)   Filing Date: 10/Sep/2012

Abstract:

The present invention relates to compounds of the formula I wherein R1 to R4 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

Priority: EP20110180936 Applic. Date: 2011-09-12

Inventor: GRETHER UWE [DE]; ROEVER STEPHAN [DE]


Publication No.: WO2013037838A1  Published: 21/Mar/2013

Title: POLYMORPHIC FORM OF PITAVASTATIN CALCIUM

Applicant/Assignee: FARMA GRS, D.O.O

Application No.: WO2012EP67859 (PCT/EP2012/67859)   Filing Date: 12/Sep/2012

Abstract:

The present invention relates to a new polymorphic form of pitavastatin calcium, a process for its preparation and a pharmaceutical composition comprising it. The new polymorphic form is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

Priority: SI20110000359 Applic. Date: 2011-09-12

Inventor: KLJAJIC ALEN [SI]; TROST SABINA [SI]; PECAVAR ANICA [SI]; ZUPET ROK [SI]


Publication No.: WO2013037889A2  Published: 21/Mar/2013

Title: VACCINE

Applicant/Assignee: AFFIRIS AG

Application No.: WO2012EP67950 (PCT/EP2012/67950)   Filing Date: 13/Sep/2012

Abstract:

The present invention relates to a vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein said at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9).

Priority: EP20110181090 Applic. Date: 2011-09-13

Inventor: BRUNNER SYLVIA [AT]; GALABOVA GERGANA [AT]; WANKO BETTINA [AT]; WINDWARDER MARKUS [AT]; WINSAUER GABRIELE [AT]


Publication No.: WO2013037894A1  Published: 21/Mar/2013

Title: DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP

Applicant/Assignee: BAYER INTELLECTUAL PROPERTY GMBH

Application No.: WO2012EP67962 (PCT/EP2012/67962)   Filing Date: 13/Sep/2012

Abstract:

The present invention relates to disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Priority: EP20110181602 Applic. Date: 2011-09-16

Inventor: LUECKING ULRICH [DE]; KOSEMUND DIRK [DE]; SCHOLZ ARNE [DE]; LIENAU PHILIP [DE]; SIEMEISTER GERHARD [DE]; BOEMER ULF [DE]; BOHLMANN ROLF [DE]


Publication No.: WO2013037905A1  Published: 21/Mar/2013

Title: USE OF 3-(R)-[3-(2-METHOXYPHENYLTHIO)-2-(S)-METHYLPROPYL]AMINO-3,4-DIHYDRO- 2H-1,5-BENZOXATHIEPINE FOR PREVENTING AND/OR TREATING CARDIOTOXIC EFFECTS CAUSED BY CHEMOTHERAPY AND/OR RADIATION

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: WO2012EP67980 (PCT/EP2012/67980)   Filing Date: 13/Sep/2012

Abstract:

The present invention relates to the use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro- 2H-1,5-benzoxathiepine or a pharmaceutically acceptable salt thereof for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation.

Priority: FR20110058155 Applic. Date: 2011-09-13

Inventor: VACHER BERNARD [FR]; LE GRAND BRUNO [FR]


Publication No.: WO2013038122A1  Published: 21/Mar/2013

Title: METHOD OF COATING MICRONEEDLE DEVICES

Applicant/Assignee: UNIVERSITY OF GREENWICH

Application No.: WO2012GB00104 (PCT/GB2012/00104)   Filing Date: 01/Feb/2012

Abstract:

Microneedle devices are spray coated by nozzles which jet dispense dots onto the individual needles of a microneedle device from a spray nozzle which is angled with respect to the plane of the microneedle device. An angle of between 70 DEG and 45 DEG is preferred and can be achieved by providing the microneedle devices on a support which is inclined at 20 DEG to 44 DEG to the horizontal and using a spray nozzle with a vertical axis.

Priority: GB20110016143 Applic. Date: 2011-09-16

Inventor: DOUROUMIS DIONYSIOS [GB]


Publication No.: WO2013038136A1  Published: 21/Mar/2013

Title: BI-AROMATIC AND TRI-AROMATIC COMPOUNDS AS NADPH OXIDASE 2 (Nox2) INHIBITORS

Applicant/Assignee: THE UNIVERSITY OF SURREY

Application No.: WO2012GB00725 (PCT/GB2012/00725)   Filing Date: 17/Sep/2012

Abstract:

Bi- and tri-aromatic compounds of the formula (I) wherein R1 to RIO and X are as defined, are Nox2 inhibitors that are useful as medicaments for the treatment of a disease or condition selected from: cardiovascular diseases, respiratory diseases, inflammatory diseases, cancers, ageing and age related disorders, kidney diseases, neurodegenerative diseases, diabetes and conditions associated with diabetes. The compounds, their preparation and pharmaceutical compositions comprising them are disclosed.

Priority: GB20110016017 Applic. Date: 2011-09-16

Inventor: LI JIAN-MEI [GB]; HOWLIN BRENDAN [GB]; MEIJLES DANIEL NATHAN [GB]


Publication No.: WO2013038137A1  Published: 21/Mar/2013

Title: METHOD OF COATING MICRONEEDLE DEVICES

Applicant/Assignee: UNIVERSITY OF GREENWICH

Application No.: WO2012GB00727 (PCT/GB2012/00727)   Filing Date: 17/Sep/2012

Abstract:

Microneedle devices are spray coated by nozzles which jet dispense dots onto the individual needles of a microneedle device from a spray nozzle which is angled with respect to the plane of the microneedle device. An angle of between 70 DEG and 45 DEG is preferred and can be achieved by providing the microneedle devices on a support which is inclined at 20 DEG to 45 DEG to the horizontal and using a spray nozzle with a vertical axis.

Priority: GB20110016143 Applic. Date: 2011-09-16; WO2012GB00104 Applic. Date: 2012-02-01

Inventor: DOUORUMIS DIONYSIOS [GB]


Publication No.: WO2013038195A2  Published: 21/Mar/2013

Title: PHARMACEUTICAL NANOPARTICLE COMPOSITIONS

Applicant/Assignee: ALTACOR LIMITED

Application No.: WO2012GB52272 (PCT/GB2012/52272)   Filing Date: 13/Sep/2012

Abstract:

This invention relates to the use of nanoparticles of glucocorticoid antagonists for the treatment of ocular and non-ocular conditions, compositions containing them and methods for the preparation thereof.

Priority: US201161534248P Applic. Date: 2011-09-13

Inventor: CRAWFORD FRANCESCA [GB]; GUNNING PHILIP [GB]; HERMANS DAVID [US]; THASSU DEEPAK [US]


Publication No.: WO2013038323A1  Published: 21/Mar/2013

Title: TASTE MASKED PHARMACEUTICAL COMPOSITIONS OF CEFUROXIME AXETIL

Applicant/Assignee: UNIMARK REMEDIES LTD

Application No.: WO2012IB54686 (PCT/IB2012/54686)   Filing Date: 10/Sep/2012

Abstract:

The invention relates to a process for preparation of taste masked and nongelling pharmaceutical compositions of Cefuroxime or its pharmaceutically acceptable salts such as Cefuroxime axetil with lipid or mixture of lipids to mask the bitter taste of Cefuroxime axetil using hot melt extrusion technique. The process comprises dispersing of Cefuroxime axetil in melted lipid or the mixture of lipids, solidification of the molten lipid or mixture of lipids on the particulate Cefuroxime or its pharmaceutically acceptable salts, and recovering said lipid or mixture of lipids coated Cefuroxime particles. The invention also relates to taste masked non gelling pharmaceutical composition of Cefuroxime or its pharmaceutically acceptable salt prepared by hot melt extrusion technique.

Priority: IN2011MU02596 Applic. Date: 2011-09-13

Inventor: NANDE VISHWANATH SUDHIR [IN]; EDATHUMPADIKKAL VALSARAJ [IN]


Publication No.: WO2013039993A1  Published: 21/Mar/2013

Title: BIORESORBABLE DRUG DELIVERY MATRICES BASED ON CROSS-LINKED POLYSACCHARIDES, DOSAGE FORMS DESIGNED FOR DELAYED/CONTROLLED RELEASE

Applicant/Assignee: ROYER BIOMEDICAL, INC

Application No.: WO2012US54794 (PCT/US2012/54794)   Filing Date: 12/Sep/2012

Abstract:

Bioactive agents are embedded in a cross-linked dextran and coated with a bioresorbable polymer. When implanted in a mammal, the coated cross-linked dextran composition produces controlled release of the embedded bioactive agent. The dosage forms according to certain embodiments of the invention described herein include implants. Although effective systemic levels of medication can be attained via implants, some of the embodiments of the dosage forms described herein are designed for localized delivery.

Priority: US201161534767P Applic. Date: 2011-09-14

Inventor: ROYER GARFIELD P [US]; BIZIKOVA TATIANA [US]


Publication No.: WO2013040417A1  Published: 21/Mar/2013

Title: AMPHIPHILIC CATIONIC POLYMERS FOR THE DELIVERY OF THERAPEUTIC AGENTS

Applicant/Assignee: THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER

Application No.: WO2012US55521 (PCT/US2012/55521)   Filing Date: 14/Sep/2012

Abstract:

Amphiphilic cationic polymers comprising a biocompatible amphiphile linked to an organic cation are provided. The polymers complex with therapeutic agents and facilitate delivery of such therapeutic agents, particularly therapeutic nucleic acids, both in vitro and in vivo. Accordingly, the invention further provides methods of facilitating delivery of therapeutic and/or diagnostic agents to a cell and methods of treating a condition, such as a disease or infection, in an organism using the amphiphilic cationic polymers of the invention.

Priority: US201161535798P Applic. Date: 2011-09-16

Inventor: WANG MINGXING [US]; LU QILONG [US]; WU BO [US]; LU PEIJUAN [US]


Publication No.: WO2013040801A1  Published: 28/Mar/2013

Title: HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF

Applicant/Assignee: GUANGZHOU ESA BIOTECH CO., LTD

Application No.: WO2011CN80213 (PCT/CN2011/80213)   Filing Date: 27/Sep/2011

Abstract:

Provided in the present invention is a hydroxamic acid compound containing quinolyl as shown in formula (I), at the same time also disclosed is the preparation method of the compound and the use thereof, and a drug containing the hydroxamic acid compound containing quinolyl. Such compounds are inhibitors of protein kinases and/or histone deacetylases, and can be used in the treatment of diseases caused by the abnormal activity of protein kinases and/or histone deacetylases, for example tumours, etc.

Priority: CN20111278403 Applic. Date: 2011-09-19

Inventor: YUN ZIWEI [CN]; WANG HONGTAO [CN]


Publication No.: WO2013041205A1  Published: 28/Mar/2013

Title: NOVEL THERAPEUTIC CONCEPTS FOR TREATING VASCULAR DISEASES

Applicant/Assignee: PYXIRION PHARMA GMBH

Application No.: WO2012EP03888 (PCT/EP2012/03888)   Filing Date: 18/Sep/2012

Abstract:

The present invention relates to the use of mycophenolic acid [also referred to synonymously as "MPA" or, according to IUPAC nomenclature, also as "(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-l,3-dihydroisobenzofliran-5-yl)-4-methyl-hex-4-enoic acid"] or its pharmacologically effective and physiologically compatible salts or esters for the curative and/or prophylactic treatment of vascular diseases.

Priority: DE201110113558 Applic. Date: 2011-09-19; DE201110115727 Applic. Date: 2011-10-12

Inventor: RUTSCHMANN ROLAND [CH]


Publication No.: WO2013041206A1  Published: 28/Mar/2013

Title: PHARMACEUTICAL COMBINATION DRUG

Applicant/Assignee: ACROVIS BIOSTRUCTURES GMBH, UNIVERSITAET ULM

Application No.: WO2012EP03889 (PCT/EP2012/03889)   Filing Date: 18/Sep/2012

Abstract:

The invention relates to a pharmaceutic combination drug containing 12-imidazolyl-1-dodecanol or a pharmaceutically acceptable salt thereof and cisplatin or a platinum complex-analogue in a weight ratio of 1 weight part 12-imidazolyl-1-dodecanol to 5 - 400 weight parts cisplatin or platinum complex analogue.

Priority: DE201110113831 Applic. Date: 2011-09-21

Inventor: DIESINGER TORSTEN [DE]; HAEHNER THOMAS [DE]


Publication No.: WO2013041435A1  Published: 28/Mar/2013

Title: COMPRESSED ORAL DOSAGE FORM FOR ASENAPINE MALEATE

Applicant/Assignee: HEXAL AG

Application No.: WO2012EP67920 (PCT/EP2012/67920)   Filing Date: 13/Sep/2012

Abstract:

The present invention relates to a compressed pharmaceutical dosage form intended for sublingual or buccal administration and capable of being rapidly disintegrated, the compressed pharmaceutical dosage form containing asenapine maleate in a microcrystalline monoclinic form. It further relates to a method of preparing the same and to a container comprising the dosage form.

Priority: EP20110182256 Applic. Date: 2011-09-21

Inventor: BORN MAX [DE]; FISCHER DIANA [DE]; OTTO INA [DE]; FISCHER YVONNE [DE]; BRAEUER CARSTEN [DE]


Publication No.: WO2013041542A1  Published: 28/Mar/2013

Title: PHARMACEUTICAL FORMULATIONS COMPRISING SPHEROLYOPHILISATES OF BIOLOGICAL MOLECULES

Applicant/Assignee:

Application No.: WO2012EP68384 (PCT/EP2012/68384)   Filing Date: 19/Sep/2012

Abstract:

The present invention relates to pharmaceutical formulations comprising monodisperse spherolyophilisates of biological molecules, to methods for making such formulations and uses thereof.

Priority: EP20110181839 Applic. Date: 2011-09-19

Inventor: LAMPRECHT ALF [DE]


Publication No.: WO2013041646A1  Published: 28/Mar/2013

Title: FORMULATION AND TREATMENT FOR ACNE

Applicant/Assignee: ELZBIETA COSMETICS BV

Application No.: WO2012EP68580 (PCT/EP2012/68580)   Filing Date: 20/Sep/2012

Abstract:

The present invention relates to composition comprising Lactobacillus rye ferment, dialkylisosorbide and phospholipid. Preferably, the composition further comprises ethoxylated sorbitan fatty acid ester. The composition has been shown to be effective against infections of closed comedones. The invention further relates to a method of preparing the composition, to a roll-on applicator comprising the composition and to the use of the composition in treatment of closed comedones infections.

Priority: EP20110182258 Applic. Date: 2011-09-21

Inventor: BRAND-GARNYS ELZBIETA EWA [NL]


Publication No.: WO2013041696A1  Published: 28/Mar/2013

Title: STIMULATING AND INVIGORATING NASAL SPRAY AND NASAL DROP

Applicant/Assignee: F. HOLZER GMBH

Application No.: WO2012EP68688 (PCT/EP2012/68688)   Filing Date: 21/Sep/2012

Abstract:

The invention relates to the use of a composition containing at least one ethereal oil and at least one simulating substance for nasal administration. The composition is introduced into the nose, in particular formulated as a nasal spray or nasal drop, but is also suitable for inhalation.

Priority: DE201110114094 Applic. Date: 2011-09-21

Inventor: LEE HYECK-HEE [DE]; STEINFELD UTE [DE]; HOLZER FRANK [DE]


Publication No.: WO2013041719A1  Published: 28/Mar/2013

Title: TRIPEPTIDE KDPT FOR ANTIAPOPTOTIC TREATMENT

Applicant/Assignee: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Application No.: WO2012EP68755 (PCT/EP2012/68755)   Filing Date: 24/Sep/2012

Abstract:

The present invention is related to the tripeptide (l)Lys-(d)Pro-(l)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti- apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis.

Priority: EP20110182561 Applic. Date: 2011-09-23

Inventor: BETTENWORTH DOMINIK [DE]; BOEHM MARKUS [DE]; LUEGERING ANDREAS [DE]


Publication No.: WO2013041851A1  Published: 28/Mar/2013

Title: NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE

Applicant/Assignee: OREXO AB

Application No.: WO2012GB52303 (PCT/GB2012/52303)   Filing Date: 18/Sep/2012

Abstract:

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly- acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Priority: US201161536180P Applic. Date: 2011-09-19

Inventor: FISCHER ANDREAS [SE]


Publication No.: WO2013041859A1  Published: 28/Mar/2013

Title: CANNABINOID-2-RECEPTOR AGONISTS

Applicant/Assignee: ISIS INNOVATION LIMITED

Application No.: WO2012GB52313 (PCT/GB2012/52313)   Filing Date: 19/Sep/2012

Abstract:

The present invention relates to cannabinnoid-2-receptor (CB2R) agonist compounds. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them and to their use as therapeutic agents for the treatment and/or prevention of diseases or conditions in which CB2R stimulation is beneficial (especially inflammatory conditions).

Priority: GB20110016152 Applic. Date: 2011-09-19

Inventor: CHRISTOU IVY [GB]; CROSS REBECCA LILLIAN [GB]; GIANELLA-BORRADORI MATTEO [GB]; GREAVES DAVID ROBERT [GB]; RUSSELL ANGELA JANE [GB]; WYNNE GRAHAM MICHAEL [GB]


Publication No.: WO2013042131A1  Published: 28/Mar/2013

Title: A PROCESS FOR PREPARATION OF SYNERGISTIC HERBAL PREPARATION OF EXTRACTS PICRORHIZA KURROA AND GLYCYRRHIZA GLABRA HAVING MEDICINAL VALUE

Applicant/Assignee: M KUMAR, ANIL

Application No.: WO2011IN00747 (PCT/IN2011/00747)   Filing Date: 27/Oct/2011

Abstract:

A synergistic herbal preparation of extracts of Picrorhiza Kurroa Royle or its close species of the same family such as Picrorhiza Scrophulariflora Pennel and Neopicrorhiza Scrophulariiflora, and Glycyrrhiza Glabra having medicinal values and Antiviral and Immune boosting activity against DNA virus -bacteriophage pi AT 300 mug/ml and plaque reduction assay

Priority: IN2011CH03286 Applic. Date: 2011-09-23

Inventor: RAO RAMANA [IN]


Publication No.: WO2013042149A1  Published: 28/Mar/2013

Title: EXTRACTS OBTAINED FROM VITIS VINIFERA SEEDS AND/OR POMACE AND/OR GREEN GRAPES AND/OR STALKS AND USES THEREOF AS ANTIFUNGAL AGENTS

Applicant/Assignee: UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA, CRA - CONSIGLIO PER LA RICERCA E LA SPERIMENTAZIONE IN AGRICOLTURA, UNIVERSITA DEGLI STUDI DI FIRENZE

Application No.: WO2011IT00400 (PCT/IT2011/00400)   Filing Date: 06/Dec/2011

Abstract:

The invention relates to extracts obtained from viticultural and winemaking supply chain's waste matter, such as: Vitis vinifera seeds and/or pomace and/or green grapes and/or stalks chemically characterized (in terms of flavan-3-ols polymers and oligomers content and their reciprocal ratios) and obtained from cultivars subjected to controlled agronomic treatments and to their use as antifungal agents. The choice of the cultivar and of the standardized water and nitrogen agronomic treatments, allow obtaining extracts that are reproducible in their content in active components and to correlate the chemical features to the antifungal activity.

Priority: IT2010RM00636 Applic. Date: 2010-12-06

Inventor: PASQUA GABRIELLA [IT]; SIMONETTI GIOVANNA [IT]; D AURIA FELICIA DIODATA [IT]; SANTAMARIA ANNA RITA [IT]; ANTONACCI DONATO [IT]; MULINACCI NADIA [IT]


Publication No.: WO2013043085A1  Published: 28/Mar/2013

Title: PHARMACEUTICAL SUBSTANCE (VARIANTS) AND COMPOSITIONS BASED THEREON WHICH EXHIBIT MODULATORY ACTIVITY WITH A COMMENSURATE EFFECT

Applicant/Assignee:

Application No.: WO2012RU00773 (PCT/RU2012/00773)   Filing Date: 20/Sep/2012

Abstract:

The invention relates to various fields of medicine, pharmaceutics and pharmacology and the chemical pharmaceutical, pharmaceutical and parapharmaceutical industry, and specifically concerns a novel class of agents which exhibit modulatory activity with a commensurate effect. The essence of the invention is that the proposed (RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide product does not contain biologically inert substances which exert a negative effect on its newly discovered or significantly improved known properties and characteristics, giving rise to hitherto unknown fundamental and highly important ideas about the compound, expanding the scope of use thereof with an increase in the effectiveness and safety of use and an increase in the therapeutic index, and making it possible to produce the product and related products with the newly found properties and characteristics.

Priority: RU20110138840 Applic. Date: 2011-09-22

Inventor: AKHAPKINA VALENTINA IVANOVNA [RU]; AKHAPKIN ROMAN VITALYEVICH [RU]


Publication No.: WO2013043387A1  Published: 28/Mar/2013

Title: OPHTHALMIC GEL COMPOSITIONS

Applicant/Assignee: BAUSCH & LOMB INCORPORATED

Application No.: WO2012US54100 (PCT/US2012/54100)   Filing Date: 07/Sep/2012

Abstract:

A suspension comprising an ophthalmic active that has a solubility in water at 25 DEG C and a pH of 7 of less than 0.1 times the concentration of the active in mg/mL in the suspension, the ophthalmic active suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, G' > G" and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 inL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G" > G' and the tear mixture has a yield value of less than 0.1 Pa.

Priority: US201113239612 Applic. Date: 2011-09-22; US201213600723 Applic. Date: 2012-08-31

Inventor: COFFEY MARTIN J [US]


Publication No.: WO2013043637A1  Published: 28/Mar/2013

Title: METHOD AND COMPOSITION FOR TREATING PAIN

Applicant/Assignee: JOHNSON & JOHNSON CONSUMER COMPANIES, INC

Application No.: WO2012US55979 (PCT/US2012/55979)   Filing Date: 19/Sep/2012

Abstract:

Presented are methods of using topical analgesic compositions for rapid relief of muscular aches and pain where the analgesic composition has been stored at a temperature of less than 10o Centigrade prior to use.

Priority: US201113235947 Applic. Date: 2011-09-19

Inventor: CHIN JENNIFER K [US]; RICK DONALD [US]; WALLACE ROSEMARIE [US]


Publication No.: WO2013043839A1  Published: 28/Mar/2013

Title: BIOSENSOR WITH ERROR COMPENSATION

Applicant/Assignee: BAYER HEALTHCARE LLC

Application No.: WO2012US56280 (PCT/US2012/56280)   Filing Date: 20/Sep/2012

Abstract:

A biosensor system determines analyte concentration from an output signal generated from a light-identifiable species or a redox reaction of the analyte. Such biosensor can for instance determine glucose concentration in blood. The biosensor system compensates at least 50% of the total error in the output signal with a primary function and may compensate a portion of the residual error with at least one residual function. A function based on segemented signal processing (SSP) may serve as the primary function, first residual function, or second residual function. Preferably, when the SSP function serves as the first residual function, the SSP function compensates at least 50% of the residual error remaining after primary compensation. Preferably, when the SSP function serves as the second residual function, the SSP function compensates at least 50% of the residual error remaining after primary and first residual compensation. The error compensation provided by the primary, first residual, and second residual functions may be adjusted with function weighing coefficients.

Priority: US201161537145P Applic. Date: 2011-09-21

Inventor: WU HUAN-PING [US]


Publication No.: WO2013043960A1  Published: 28/Mar/2013

Title: COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE

Applicant/Assignee: VERTEX PHARMACEUTICALS INCORPORATED

Application No.: WO2012US56474 (PCT/US2012/56474)   Filing Date: 21/Sep/2012

Abstract:

The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Priority: US201161537916P Applic. Date: 2011-09-22

Inventor: EVERITT SIMON [GB]; KNEGTEL RONALD [GB]; MORTIMORE MICHAEL [GB]; RUTHERFORD ALISTAIR [GB]


Publication No.: WO2013044098A1  Published: 28/Mar/2013

Title: COMPOSITIONS AND METHODS FOR TREATING CONDITIONS OF COMPROMISED SKIN BARRIER FUNCTION

Applicant/Assignee: LIVING PROOF, INC

Application No.: WO2012US56667 (PCT/US2012/56667)   Filing Date: 21/Sep/2012

Abstract:

Compositions and methods of treating conditions of compromised skin barrier function are described.

Priority: US201161537307P Applic. Date: 2011-09-21; US201261607908P Applic. Date: 2012-03-07; US201261607905P Applic. Date: 2012-03-07

Inventor: YU BETTY [US]; LOMAKIN JOSEPH [US]; KANG SOO-YOUNG [US]; ADAMS BENJAMIN W [US]

WORLD PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL ACTIVES PUBLISHED IN 2013
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications. Salient
search terms included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained
drug release; polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal,
nasal, ocular or buccal administration of medications, etc.
World Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Published in 2013
Clck to enlarge and view details
  PAGE 1
World  Patents Published  in 2013 - Page2
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..